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ABSTRACT 
The focus of this project is to study the structure and function of the polymerase 
polyprotein of mouse hepatitis virus (MHV). I have concentrated on identifying the 
processed products of the polymerase polyprotein and the mechanism by which these 
products are generated. The polymerase gene of MHV encodes a polyprotein of greater 
than 750 kDa which contains three proposed proteinases, PCP-1, PCP-2 and 3C. PCP-1 
cleaves p28 from the amino terminus of the polyprotein in vitro (Baker et al., 1989). 
To identify other protein products downstream of p28, I developed an antiserum directed 
against a portion of a predicted polypeptide adjacent to p28. This antiserum 
immunoprecipitated two proteins of approximate Mr 73 kDa and 65 kDa from MHV-
JHM infected cells. Pulse and chase labeling experiments and immunoprecipitation 
analysis showed that p73 was chased away while p65 was accumulated during the chase. 
These data indicate that p73 is a precursor of p65. These results suggest that a novel 
proteolytic pathway is utilized to process these products from the polymerase polyprotein 
of MHV. The first event in this proteolytic pathway is the cleavage of the amino-
terminal protein, p28. The second event is the release of a 73 kDa protein from the 
polymerase polyprotein. The 73 kDa protein is then further processed to generate a 65 
kDa protein product. 
The polyprotein processing was further studied by expressing cDNA clones 
representing the 5'-most 6.8 kb of the polymerase gene in vitro by using a rabbit 
Xl 
reticular lysate transcription/translation system and, in vivo, by using a recombinant 
vaccinia virus expression system. These cDNA clones encoded the p28, p65, p73, PCP-
1 and PCP-2 domains. The results of the expression studies showed that, although p28 
was efficiently processed from its precursor, p73 and p65 were not. These data indicate 
that proteinase PCP-1 and predicted proteinase PCP-2 are not responsible for cleaving 
p73 and p65 from the polyprotein. Based on above evidence, I hypothesize that p73 and 
p65 are generated by the activities of the 3C-like proteinase domain of coronavirus. 
I investigated the functions of the MHV polymerase polyprotein products by 
characterizing a series of temperature sensitive (ts) mutants that do not synthesis RNA 
at nonpermissive temperature. The mutation(s) responsible for the ts phenotype had 
previously been mapped to the 5'-end of the polymerase gene, potentially in the p28, 
p65, p73 or PCP-1 domains. A putative ts mutation was identified by sequencing one 
of the ts mutants, NCll, which was defective in generating p28 at nonpermissive 
temperature. To determine if the mutation renders the ts phenotype, defective 
interfering RNA mediated RNA recombination was used to replace the mutation in vivo. 
I demonstrated that the 5'-most genome sequences of the ts mutant NCl 1 was replaced 
by the substrate RNA through RNA recombination. Although the mutation was 
substituted with wild type sequence, no recombinant viruses that exhibited wild 
phenotype were detected. This result indicates that NCl 1 may have multiple mutations 
that are responsible for the ts phenotype. This genetic study of the ts mutants has 
demonstrated the feasibility of using RNA recombination to study the functions of the 
polymerase polyprotein products in ts mutants of MHV. 
XU 
Corona viruses 
CHAPTER I 
LITERATURE REVIEW 
Coronaviruses are a family of large, spherical, enveloped RNA viruses with 
prominent surface projections covering the entire virion surface. They infect various 
animal species, causing respiratory, gastrointestinal and neurological diseases. In 
humans, coronaviruses have been shown to cause common cold, diarrhea and possibly 
multiple sclerosis (Wege, et al. 1982; Siddell, S., 1983; Lai, 1990; Spann et al., 1990). 
In order to control these veterinary and human diseases, extensive studies have been 
concentrated on examining the epidemiology and the mechanism of transcription and 
replication of coronaviruses. One of the best-studied members of this virus family is 
mouse hepatitis virus (MHV) (Sturman et al., 1983; van der Most et al., 1991). MHV 
is the prototype coronavirus and is used throughout my studies. 
Structure of the Virion 
The MHV virion possesses three major structural proteins: a large spike glycoprotein 
(S), a small integral membrane protein (M) and a nucleocapsid protein (N). A fourth 
structural protein on the virion surface of some strains of MHV is the hemagglutinin-
esterase (HE) protein (Yokomori et al., 1989). 
The spike protein is on the virion envelope. The approximate molecular weight is 
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180 kDa, and the spike is cleaved into two proteins of 90 kDa. This cleavage has been 
shown to be mediated by cellular proteinases and is required for the activation of viral 
infectivity (Sturman et al., 1985). This spike protein is the ligand that binds to the 110 
kDa glycoprotein, carcino-embryonic antigen (CEA), on the target cell surface, and 
mediates cell-to-cell fusion as well as the virus entering the cell (Dveksler et al., 1991; 
Williams et al., 1991). The spike protein also elicits neutralizing antibodies and cell 
mediated immunity (Sturman et al., 1983). Monoclonal antibodies specific for the S 
protein can neutralize virus infectivity and inhibit the fusion-inducing ability of the virus 
(Collins et al., 1982; Wege et at., 1984). 
The second viral structural protein is a small integral membrane glycoprotein (M). 
Amino acid and biochemical analysis have shown that this protein is hydrophobic and 
spans the viral envelope several times (Armstrong et al., 1984; Rottier et al., 1986). 
It functions as a component of the envelope and the inside domain of the M protein may 
interact with the virion nucleocapsid in the assembly of the virus particles (Sturman et 
al., 1980; Tooze et al., 1984). 
The third viral structural protein is an internal component of the virus. This protein, 
N, is a phosphoprotein of 50 kDa (Stohlman et al., 1979), which binds to virion RNA, 
providing the structural basis for the helical nucleocapsid. The protein seems to bind 
to the area of nucleotide 56-65 of the leader sequence of MHV (Stohlman et al., 1988). 
In addition to its role in encapsidating genomic RNA and facilitating its incorporation 
into virions, the N protein has been implicated in the process of RNA replication. 
Addition of antiserum raised against N (but not against S or M) to an in vitro replication 
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system inhibited the synthesis of genome-sized RNA by 90% (Compton et al., 1987), 
and this antiserum co-immunoprecipitated MHV-specific RNAs found in infected cells 
(Barie et al., 1988). 
The HE protein, the fourth structural protein on the virion surface is glycosylated 
by the N-linked carbohydrates and constitutes the smaller spikes observed on the virion 
surface. The presence of this glycoprotein is optional in that only some MHV strains 
have the HE protein (Yokomori et al., 1989). An interesting facet of this glycoprotein 
is that it shares some sequence homology with the hemagglutinin protein of influen7.a C 
virus (Luytjes et al., 1988). Some strains of MHV have been shown to possess esterase 
activity (Yokomori et al., 1989). However, HE protein is dispensible in vitro; its 
function in vivo remains to be determined. 
Replication Cycle of Coronavirus MHV-JHM 
Coronavirions attach to receptors on the membrane of target cells by binding to 
carcinoembryonic antigen (CEA) (Williams et al., 1991). Once the viral RNA genome 
is released into the cells, the subsequent biochemical events in the viral replication cycle 
take place entirely in the cytoplasm of infected cells and can occur normally in 
enucleated cells (Wilhelmsen et al., 1981). The virion does not carry its own RNA-
dependent RNA polymerase in the virus particle. Because there is no RNA-dependent 
RNA polymerase available within the host cell, the virus has to synthesize its own 
polymerase for viral transcription and replication. Upon entry into the host cell, the 
viral genomic RNA is first translated to generate an RNA-dependent RNA polymerase. 
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Subsequently, this virus-encoded RNA-dependent RNA polymerase transcribes the 
incoming viral genomic RNA into full-length negative-stranded RNAs. The genomic-
length negative-stranded RNA will be used as a template for the synthesis of the virus-
specific subgenomic mRNAs and the positive sense genomic RNA (Lai et al., 1982). 
The messenger RNAs are used to synthesize the viral structural and nonstructural 
proteins. The assembly of virions is first initiated by the formation of the helical 
nucleocapsid through the interaction of newly synthesized genomic RNA with the 
molecules of the N protein. Subsequently, the virus nucleocapsid buds into membranes 
of the endoplasmic reticulum and, in the process, acquires lipid bilayer and Sand/or HE 
proteins. The mature virion particles are transported across the Golgi apparatus and 
then are released by cell lysis or by fusion of post-Golgi, virion-containing vesicles with 
the plasma membrane. The entire life cycle of MHV takes place in cytoplasm of 
infected-cells and this cycle takes 8 hrs-12 hrs to complete from the entry of MHV into 
susceptible cell to the release of progeny virion. 
Genome Structure and Polymerase Polyprotein 
MHV has a single-stranded, nonsegmented, positive-sense RNA genome (Fig. l) (Lai 
et al., 1978; Wege et al., 1978). The 31-kb genome is composed of eight genes. Four 
genes encode virion structural proteins, as described above, and the other four genes 
encode nonstructural proteins. The RNA genome is 5' capped and 3' polyadenylated 
and is infectious upon transfection into a susceptible cell line (Schochetman et al., 1977). 
The polymerase gene of MHV-JHM spans two thirds of the genome, is 22 kb in length, 
5 
and has been completely cloned and sequenced (Pachuk et al., 1989; Lee et al., 1991). 
The polymerase gene contains two open reading frames named ORFla (13.6 kb) and 
ORFlb (8.2 kb). ORFlb overlaps ORFla by 75 nucleotides, and ORFlb is in minus 
1 reading frame of the ORF la. It has been proposed that the entire polymerase gene can 
be translated into one polyprotein of about 750 kDa by a ribosomal frameshifting 
mechanism (Brierly et al., 1987; 1989; Bredenbeek et al., 1990; Lee et el., 1991). The 
deduced amino acid sequence analysis suggests that the polymerase polyprotein contains 
polymerase, helicase, and zinc-finger motifs, as well as several other domains (see 
Introduction section) (Gorbalenya et al., 1989; Bredenbeek et al., 1990). 
Leader Primed Transcription 
The unique transcription of coronavirus RNA has been studied in infected cell lines 
and in cell-free extracts. The RNAs are transcribed from the a full-length negative 
strand RNA to form a nested set of mRNAs. These mRNAs are capped at the 5'-end 
and are polyadenylated at the 3 '-end. They have the same 3 '-end but differ in length 
at the 5'-end (Lai et al., 1983). The largest mRNA is identical to the virion genomic 
RNA. Only the 5' region of each mRNA that does not overlap with the next smaller 
mRNA is translated (Siddell, 1983). Each mRNA contains a small leader RNA of about 
72 nucleotides at the 5'-end, which is derived from the 5'-end of the RNA genome (Lai 
et al., 1983; 1984; Spaan et al., 1983). Furthermore, ultraviolet transcriptional mapping 
studies have shown that the ultraviolet target sizes calculated for the templates were 
6 
Figure 1. Schematic representation of the polymerase gene and open reading frames 
(ORF) of Mouse Hepatitis Virus strain JHM (MHV-JHM). The positions of p28, the 
papain like cysteine proteinase domain 1 (PCP-1), the predicted papain like cysteine 
proteinase domain 2 (PCP-2), the putative polio virus 3C-like proteinase domain (3C), 
The proposed polymerase domain (POL), zinc finger domain (Zn finger) and helicase 
domain (HEL) are shown. Two ORFs of the polymerase gene are proposed to be 
translated into a single polyprotein, which is larger than 750 k:Da. The scale is kilobases 
(kb) is listed at the bottom of the figure. 
MHV Polymerase Polyprotein 
MHV-JHM s• Polymerase gene 3• 
Genomic RNA I AAA 
Polymerase 
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almost identical to the physical sizes of the RNAs and have indicated that each mRNA 
is transcribed independently and not derived from the processing of a large precursor 
RNA (Jacobs, et al., 1981). To explain this phenomenon, a "leader-primed" 
transcription model has been proposed as the transcription mechanism for coronavirus 
(Fig. 2). In this model, a leader RNA of about 72 nucleotides is transcribed from one 
end of the genomic-length negative-strand RNA template. The leader RNA then 
dissociates from the template RNA and rejoins the template RNA at downstream internal 
transcription initiation sites, to serve as a primer for further transcription of mRNA. 
This model suggests that coronavirus RNA synthesis is discontinuous. Other evidence, 
especially the findings of subgenomic negative strands and a replicative form of RNA 
in the infected cell (Sawicki et al., 1990; Sethna et al., 1989; 1991), suggest that the 
subgenomic amplification may also play a role in viral replication. 
High Frequency RNA Recombination 
The replication of coronavirus has two unique features in its replication: one is the 
leader-primed transcription, as described above, and the other is the high frequency of 
RNA recombination. The extremely high frequency of RNA recombination in 
coronavirus replication is well characterized (Lai et al., 1985; Makino et al., 1986; 
Sturman et al., 1980). MHV has been demonstrated to undergo recombination both in 
tissue culture (Lai et al., 1985; Makino et al., 1986; Keck et al., 1987; 1988) and in 
infected animals (Keck et al., 1988). Makino and colleagues have suggested that the 
high frequency of recombination might be due to the discontinuous and nonprocessive 
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Figure 2. Model ofleader-primed transcription of coronavirus. Structures of the nested 
MHV mRNAs and positive and negative-strand RNA template are shown. The gray 
boxes represent the leader RNAs, which are first synthesized from negative template and 
then bind to the intergenic sites (white box) on negative template RNA to make seven 
mRNA species. Antileader sequence is indicated as a black box. 
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mode of RNA replication (Makino et al., 1986). The homologous RNA recombination 
in coronavirus-infected cells may occur via the template switching (copy-choice) 
mechanism (Cooper et al.,1974). The basic concept is that the polymerase complex that 
contains nascent RNA chain may dissociate from its original template and anneal to 
another template, after which RNA synthesis resumes. This mechanism would predict 
the generation of freely dissociated nascent RNA fragments during MHV RNA 
replication (Keck et al., 1988; Liao et al., 1992). These dissociated RNA transcripts 
could bind to different RNA templates and proceed in RNA synthesis, resulting in the 
generation of recombinant RNA (Makino et al., 1986). 
Recombination analysis of ts mutants of MHV showed that RNA recombination 
frequency approaches 17% (Barie et al., 1990). The ts mutants used in the 
recombination analysis have been mapped to the polymerase gene, which spans the 5'-
most 22-kb sequence of the genome (Fig. 3). If we assume that recombination is 
random, it has been suggested that this recombination will be at a frequency approaching 
25% for the entire genome (Barie et al., 1990). 
Temperature Sensitive Mutants of .MHV 
Temperature sensitive (ts) mutants of animal viruses are useful for assigning 
particular biochemical functions to individual viral genes or gene products because of 
their conditional-lethal phenotype (Fields et al., 1989). The ts mutants are produced by 
missense mutations that change the nucleotide sequence of a gene so that the resulting 
protein product is unable to maintain its functional configuration at nonpermissive (high) 
12 
Figure 3. Tentative map domains for the MHV-A59 ts mutant complementation groups. 
The boxed regions represent the putative domains of each MHV-A59 complementation 
group, and the probable functions of several groups are predicted. The protein products 
of the subgenomic mRNAs are also indicated as well as the putative polymerase products 
encoded in the genomic RNA. Hatched regions represent areas of overlap between the 
various complementation groups (from Barie et al., 1990). 
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temperature. That is why ts mutants can not grow at high temperature. At permissive 
(low) temperature, the protein may maintain a configuration suitable for normal function. 
Since ts mutants have conditional-lethal phenotype, they have been used to identify the 
function of every gene in influenza virus (Scholtissek, 1979). The early genetic analysis 
of ts mutants of MHV-JHM was reported by Leibowitz and his colleagues in 1982. 
They analyzed a total of 37 ts mutants isolated by Haspel et al. and Robb et al. (Haspel 
et al., 1978; Robb et al; 1979) and identified six nonoverlapping complementation 
groups that did not synthesize viral RNA at nonpermissive temperature (Leibowitz et al., 
1982). A panel of 26 ts mutants has been generated from MHV-A59 by Barie and his 
colleagues, and these mutants are defective in RNA synthesis at the nonpermissive 
temperature (Barie et al., 1990). By complementation experiments, these ts mutants 
have been divided into six groups. Temperature shift experiments indicate that five of 
the RNA complementation groups are blocked in RNA synthesis. Genetic recombination 
analysis has revealed that these groups are mapped within the polymerase gene and are 
encoded in a linear array at the 5' of the genome, in the sequence of A, B, C, D, E 
from the 5'-end to the 3'-end of the polymerase gene (Fig. 3). 
Complementation groups A and B are mapped to the 5' -end region that spans 
approximately 10 kb nucleotide sequences of the polymerase gene. This region encodes 
two proposed viral proteinase domains, p28 and other proteins. It has been shown that 
a viral proteinase activity resides at the 5 '-end 3. 6 to 4. 4-kb region of the genome. This 
proteinase is responsible for the cleavage of p28, which is the N-terminal subunit of the 
polyprotein (Soe et al., 1987; Baker et al., 1989). Little is known about the functions 
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of the processed products and the proteolytic processing of the polymerase polyprotein 
in MHV-JHM. Proteolytic processing of the viral polyprotein has been shown to play 
a key role in the regulation of viral replication and transcription in the Polio and Sindbis 
viruses (Hahn et al., 1989; Palmenberg, 1990). These ts mutants of MHV mentioned 
above are useful in our study to identify the function of p28 and the role of the 
polyprotein processing in viral RNA synthesis. 
Defective lnterf ering Particles 
Defective interfering (DI) particles have been described in all virus groups (Huang 
et al., 1977; Holland et al., 1980). The DI particles contain parts of the viral genome, 
replicate only in the presence of the helper virus and interfere with replication of the 
homologous virus (Fields et al., 1991). Makino and his colleagues reported in 1984 that 
DI particles of MHV-JHM were generated by serial undiluted passages of MHV-JHM 
(Makino et al., 1984). Several novel species of single-stranded defective particles were 
identified from passages 3 through 22 of MHV-JHM by RNase Tl-resistant 
oligonucleotide fingerprinting (Makino et al., 1985). These Dis contained different 
subsets of the genomic sequences from those of the standard intracellular mRNAs of 
nondefective MHV-JHM strain. The smallest DI particle identified by Makino and 
associates (Makino et al., 1985) is designated DlssE (Fig. 4), which is 2.2 kb in length. 
DlssE can replicate itself in the presence of helper virus and became a predominant 
RNA species in the infected cells (Makino et al., 1988). DlssE RNA is composed of 
three noncontiguous regions: I and II, which represent the first 864 nucleotides of the 
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Figure 4. Structure of defective interfering (DI) RNA DlssE. A comparison between 
the sequences of DlssE RNA and those of standard MHV-JHM genomic RNA. DlssE 
is composed of three noncontiguous regions: I and II, which represent the first 864 
nucleotides of the 5'-end and an internal 748 nucleotides of the polymerase gene, and 
region III, which contains 601 nucleotides from the 3'-end of the parental MHV 
genome. 
MHV 
Genome 
31 kb 
DlssE 
2.2kb 
Structure of Defective Interfering RNA DlssE 
1 2 3 4 5 6 7 
II 
864 nt 748 nt 601 nt 
AAA 
AAA 
--.J 
18 
5'-end and an internal 748 nucleotides of the polymerase gene, and region III, which 
contains 601 nucleotides from the 3'-end of parental MHV-JHM genome. A DissE-
based plasmid, which contains the full sequence of a small DI particle--DissE, has been 
constructed to study the mechanism of synthesis of DI RN As (Makino et al., 1988; 
1989). I took advantage of the smallest DI particle, DissE, and used it in my studies 
of ts mutants of MHV. 
CHAPTER II 
INTRODUCTION 
The goal of this project is to study the structure and function of the polymerase 
polyprotein of mouse hepatitis virus (MHV). I have concentrated on identifying the 
processed products and functions of the polymerase polyprotein and the mechanism by 
which these products are generated. 
Proteolytic Proc~ing of the Polymerase Polyprotein 
There are several functional domains in ORFla, including trans-membrane regions, 
cysteine-rich domains, and three proteinase domains, as defined by sequence analyses 
(Gorbalenya et al., 1989; Bredenbeek et al., 1990; Lee et al., 1991). Gorbalenya et al. 
proposed that there were three proteinase domains, two papain-like cysteine proteinases 
(PCP-1 and PCP-2) and a poliovirus 3C-like proteinase (3C) that are responsible for 
proteolytic processing of the large polymerase polyprotein of MHV. The actual 
evidence that support Gorbalenya's proposal came early in 1986. Denison and Perlman 
reported that the predominant in vitro translation products of the MHV genomic RNA 
are a 28 kDa protein and a 220 kDa protein. In the presence of proteinase inhibitor 
ZnC12, the dominant product is a 250 kDa protein, indicating that the appearance of p28 
could be inhibited by the addition of the proteinase inhibitor. This suggests that p28 was 
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processed from a 250 kDa precursor polyprotein (Denison and Perlman, 1986). This 
was the first evidence to show that coronavirus polymerase polyprotein underwent 
proteolytic processing. 
By two-dimentional gel electrophoresis p28 was also detected from MHV-infected 
cells indicating that proteolytic processing is taking place in vivo (Denison and Perlman, 
1987). Translation analysis of the 5'-end sequences of MHV polymerase gene 
demonstrated that p28 was the amino-terminal portion of the polymerase polyprotein 
(Soe et al., 1987). Furthermore, from translation of RNAs that represent up to 5.3 kb 
of the 5'-end of the MHV genome, Baker et al. showed that the processing of p28 was 
an autoproteolytic event in which a downstream domain was required for the cleavage 
of p28 (Balcer et al., 1989). The downstream domain, which is a pa.pain-like cysteine 
proteinase (PCP-1) is responsible for cleaving p28 (Balcer et al., 1993). Several 
peptides, ranging from 32 kDa to 90 kDa, were also identified from the C-terminal 
portion of the polymerase polyprotein by immunoprecipitating the proteins translated 
in vitro from the MHV genomic RNA by using two fusion antibodies against a portion 
of the polyprotein encoded by the 3 '-end 2,-kb sequence of the polymerase gene (Denison 
et al., 1991). 
I endeavored to identify the processed products and the functioal role of proteolytic 
processing of the polymerase polyprotein of MHV. It has been shown that the 
proteolytic processing of the polymerase polyprotein plays a critical role in the 
replication and transcription of another positive-strand RNA virus, Sindbis virus (Shirako 
et al., 1994). Shirako reported that, if the proteolytic processing of the polymerase 
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polyprotein is blocked, then the virus's RNA synthesis will be stopped, indicating that 
proteolytic processing of the polymerase polyprotein is an important step in virus 
replication and transcription (Shirako et al., 1994). Indeed, the latest evidence reported 
by Denison and associates, at the Thirteenth Annual Meeting of American Society of 
Virology, demonstrated that if the proteolytic processing of the polymerase polyprotein 
is blocked by cysteine proteinase inhibitor E64d, then virus transcription and replication 
will be arrested (Denison et al., 1994). The data from the E64d inhibition studies 
indicate that coronavirus transcription and replication require continuous proteolytic 
processing of the polymerase polyprotein. Identifying the proteolytic processing of the 
polymerase polyprotein and the functional subunits or mutual products of the polyprotein 
will greatly increase our knowledge of the coronavirus and its replication cycle and will 
strengthen the way we fight the diseases caused by coronaviruses. 
Identifying the Processed Products of the Polymerase Polyprotein of MHV 
The focus of the experiments in this dissertation is to elucidate the proteolytic 
processing pathway of the polymerase polyprotein of MHV. The key question is what 
are the processed products downstream of p28 and how are they generated? Initial 
experiments involved developing a specific antibody against a region after p28 and 
investigating the processed products of the polymerase polyprotein in an in vitro 
transcription and translation system. 
Subsequent experiments involved in vivo studies of the proteolytically processed 
products of the polymerase polyprotein by metabolic labeling and immunoprecipitation 
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as well as dynamic study of the viral polyprotein processing. These experiments 
revealed the evidence regarding the proteolytic processing pathway of the polymerase 
polyprotein of MHV and products downstream of p28. 
Another set of experiments addressed the question as to which proteinase is 
responsible for releasing the protein products from the polyprotein, both in vitro and in 
vivo. These experiments involved the use of cDNA clones of the polymerase gene to 
study the proteolytic processing of the polymerase polyprotein both by in vitro 
transcription and translation in rabbit reticulate lysate and in vivo expression in a 
recombfnant vaccinia virus expression system. These in vivo experiments also addressed 
the question as to whether a host factor is involved in the proteolytic processing of the 
polymerase polyprotein. 
Another major avenue of experimentation I investigated was to determine the 
function of the polymerase polyprotein product in virus transcription and replication. 
In these experiments, I explored a targeted RNA recombination system in vivo to map 
and rescue ts mutants. The development of such a system will allow for a detailed 
genetic and functional analysis of the functions of the polymerase polyprotein products 
ofMHV. 
Cells and Viruses 
CHAPTER ID 
.MATERIALS AND METHODS 
Monolayer cultures of DBT cells, a mouse astrocytoma cell line (Hirano, et al., 
1974) were grown in IX Modified Eagle's Media (MEM) containing 5 % fetal calf serum 
(FCS), 10% tryptone phosphate broth (TPB), 2 % glutamine (Gibco-BRL, Gaithersberg, 
MD), 2% penicillin/streptomycin (penicillin 5,000 units/ml, streptomycin 5,000 µg/ml, 
Gibco-BRL, Gaithersberg, MD). 
The IHM strain of mouse hepatitis virus (MHV-JHM) was propagated in DBT cells 
as described (Makino et al., 1984). Briefly, DBT cells (150 mm dish, 1.0 X 107 cells 
per dish) were infected with 3 ml MHV-JHM (diluted with unsupplemented MEM to an 
MOI of 0.1) and incubated at 37°C for 1 hr with rocking every 15 min. After the 1 hr 
infection, virus inoculum was removed, and 30 ml fresh MEM was added and incubated 
at 37°C for 23 hrs. Progeny viruses were harvested by collecting supernatant from the 
150 mm dish and by centrifugation at 1,300 x g for 10 min in a table top silencer 
centrifuge (model S-103NA, Rupp and Bowman Company, Texas) to pellet cell debris. 
The supernatant was aliquoted (3 ml/tube) and frozen at -7ffC until use. The titer of 
the virus stock was determined by plaque assay on DBT cells. 
In the biochemical labeling experiments, monolayer cultures of 17Cl-1 cells, a mouse 
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fibroblast cell line (Sturman et al., 1972) maintained in lX Dulbecco's Modified Eagle 
Medium (DMEM) supplemented with 5% FCS, 10% TPB, 2% glutamine, 2% 
penicillin/ streptomycin (Gibco-BRL, Gaithersberg, MD). 
Plaque As.uy 
DBT cells were grown in MEM media to confluence in 60 mm dishes. Virus stock 
was diluted in unsupplemented media to the desired dilutions (usually in 10-s, 10-6 and 
10-1 dilutions). Cell culture media was aspirated, and the cells were washed once with 
PBS. The cell monolayer was inoculated with 200 µl of the diluted virus sample and 
incubated for one hour at 37°c with rocking every 15 min. Following the 1 hr 
infection, the inoculum was removed and replaced with a 5-ml mixture (1:1 by volume) 
of 0.8% Noble agar (DIFCO, Detroit, MI) and 2X MEM. After the agar had solidified 
at room temperature for 30 min, the dishes were transferred to the 37°C incubator 
containing 5 % C02 and were incubated for 48 hrs. Plaques were visualized by staining 
with 2 ml 2% (v/v) Neutral Red solution (Gibco-BRL, Gaithersberg, MD). 
Generation of Anti-647 Antiserum 
The bacteria expression vector, pGEX-KG, which contains the glutathione S-
transferase (GST) gene under the control of a tac promoter, was kindly provided by Dr. 
Steven Broyles (Purdue University, West Lafayette, IN). The 5'-half of the tac 
promoter is derived from the Tryptophan promoter and the 3 '-half is derived from the 
Lactose promoter. Expression of the fusion-genes under the control of the tac promoter 
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is highly inducible upon the addition ofIPTG (isopropyl-1-thio-P-D-galactoside) (Amann 
et al., 1985). To generate a GST-MHV fusion protein, a 647 base pair (bp) Xho I 
fragment (nucleotides 1129 to 1776 of MHV-JHM), was isolated from pT7-NBgl 
plasmid DNA and ligated into the Xho I site of pGEX-KG (Fig. 5). The ligated DNA 
was used to transform ;B. ~ strain DH 5a (Low et al., 1968). The resultant 
expression plasmid was designated pGEX-647 and used to transform ;B. ~DH 5a by 
using a standard trasformation protocol (Maniatis et al., 1989). The expression of the 
fusion protein was induced by the addition of IPTG to the liquid bacteria cultures (Guan 
et al., 1991). Briefly, overnight cultures of E. ~DH 5a containing pGEX-647 were 
diluted by twenty-fold in fresh 2X-YT medium (Maniatis et al., 1989) containing 
ampicillin (100 µg/ml) and were then grown to an 00600 of 0.6. IPTG was added to a 
final concentration of 0.3 mM. After 3 hrs incubation at 37°C, 10-ml cultures were 
harvested and resuspended in 1/50 volume of PBS containing 1 % Triton X-100, and 
were lysed by sonication at scale 35% with a microtip (Sonic dismembrator, model 300, 
Fisher Scientific, Fairlawn, NJ) for 40 seconds and centrifuged at 10,000 x g for 5 min 
at 4°C to separate the soluble and insoluble fractions. The GST-647 protein was 
detected in the insoluble fraction by 10% SOS-PAGE analysis. The insoluble fraction 
was mixed with 50 µl 2X sample buffer (Laemmli, 1971), boiled for 2 min and 
centrifuged for 5 min. Then the supernatant was analyzed by electrophoresis on a 10 % 
polyacrylamide gel containing 0.1 % SOS. The gel was stained in 2 % Commassie blue 
for 30 min and washed in 10% acetic acid for 1 h with two changes of the 10% acetic 
acid. The large fusion protein bands (generated from the 10-ml bacteria culture), were 
26 
Figure 5. Schematic diagram of OST-fusion plasmid pGEX-647. A 647-bp 
fragment of the cDNA sequences of coronavirus polymerase gene from nucleotide 
position 1129 to 1776 of pTI-NBgl was cut out and inserted into polycloning site of 
glutathione S-transferase (OST) expression vector pGEX-KO. The resulting plasmid was 
named pGEX-647. 
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cut out, smashed and mixed with complete or incomplete Freund's adjuvant. A rabbit 
was injected subcutaneously and intramuscularly with the fusion protein mixture, as 
indicated in the Results section. 
After four immunizations, the titer of antiserum was evaluated by ELISA (Douillard 
et al., 1983) against the fusion protein immunogen together with the GST protein alone 
and with PBS, as positive and negative controls, respectively. Briefly, 100 µl of protein 
preparation of whole cell lysates in PBS (20 ng protein/100µ1 PBS) was used to coat 
each well of a 96-well plate at 4°C overnight. The antiserum was diluted in PBS from 
10-1 to lo-4 and was used in the standard ELISA assay with staphylococcus protein A 
horseradish peroxidase conjugate and OPD substrate (0-phenylene diamine from Sigma). 
The result of ELISA was measured at 490 nm in an automated ELISA reader (model BT 
200, Bio-tek Instruments Inc. Winooski, VT), and the representative data are presented 
in Table 2 of the Results section. The specific antiserum thus generated was designated 
anti-647. 
In Vitro Transcription and Translation 
Plasmids encoding the 5'-most 5.3 kb and 6.8 kb of the MHV-JHM polymerase 
gene, pTI-NBgl and pT7-NA6, have been previously described (Baker et al., 1989). 
Plasmid DNA was linearized by EcoR I digestion, purified by phenol-chloroform 
extraction and ethanol precipitation, transcribed and translated in vitro in a transcription-
translation· coupled system (TNT system, Promega Corp, Madison, WI). Briefly, 
approximately 1 µg of linearized plasmid DNA was mixed with 12.5 µl of TNT rabbit 
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reticulocyte lysate, 1 µl of TNT reaction buffer, 0.5 µl of T7 RNA polymerase, 20 units 
of RNasin, an RNase inhibitor (Promega Corp, Madison, WI), 1 µl of 1 mM 
methionine-free amino acid mixture, and 20 µCi [35S] methionine (Amersham Corp. 
Arlington Heights, IL). The 25 µl reaction mixture was incubated at 3<>°C for 90 min. 
The transcription and translation reaction was stopped by the addition of 25 µl 2X 
Laemmli sample buffer (Laemmli, 1971) containing 5% B-mercaptoethanol and 3% 
SDS. The translation products were kept at -7CfC until they were analyzed by 
immunoprecipitation and SDS-PAGE. 
TCA Precipitation 
The incorporation of radio labeled amino acids into proteins was measured by the 
trichloroacetic acid (TCA) precipitation (Maniatis et al., 1989) of the proteins followed 
by scintillation counting. Monolayers of 17Cl-1 cells (confluent in 60-mm dish, 
1.5x1<>6 cells per dish) were infected with MHV-JHM at an MOI of 10. One hour later, 
virus inoculum was replaced with DMEM supplemented with 5% FCS, 5% TPB, 2% 
glutamine, and 2 % penicillin/streptomycin. At 6.5 hr after-infection, the media was 
replaced with methionine-free media for 30 min. The infected-cells were then labeled 
with 200 µCi of [35S] methionine (Translabel, ICN, Costa Mesa, CA) per ml, per 60-
mm dish for various time length up to 2 hrs. At each time point, the media was 
removed, cells were washed twice with cold PBS. Cells were then lysed by the addition 
of 300 µVdish (1.5 X 1<>6 cells) of 2X lysis buffer, containing 4% SDS, 3% DTT, 40% 
glycerol and 0.0625 M Tris-HCl, pH 6.8. Cell lysates were harvested and .used for 
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TCA precipitation analysis. Whatman 3 mm filter-paper diskes (2.5 cm in diameter) 
were spotted with 100 ul of solution A (3% CAA, 1 % SOS), and air-dried for 0.5 hr. 
10 ul of whole cell lysates prepared from virus-infected cells were spotted at the center 
of the filter paper and air-dried for 20 min. (10 ul of in vivo unlabeled virus-infected 
cell lysates was used to determine the background radioactivity incorporation). The 
filters loaded with samples were transferred into a capped tube (50 ml, 6 paper filters 
per tube) and washed in 40 ml of Solution B (10% TCA, 3% CAA, 1 % SOS), by gentle 
shaking in an orbital shaker (Bellco Biotech, New Jersey) for 30 min at room 
temperature. The used solution B and other solutions used in the TCA analysis were 
carefully discarded. 40 ml of Solution C (5% TCA, 1.5% CAA) was added to the tube. 
The filters were incubated in a 85°C water bath for 20 min. The filters were then 
washed twice for 5 min with 40 ml of 5 % TCA and once with 40 ml of 95 % ethanol for 
5 min. The filters were rinsed twice with dH20 and air-dried for 1 hr. Each dried 
filter was transferred to a plastic scintillation vial and 4 ml of biodegradable counting 
cocktail Econo-Safe™ (Research Products International Corp. Mount Prospect, IL) were 
added to the vials. The vials were then counted in a scintillation counter (Beckman 
model LS 5801, Fullerton, CA) by USER 2 program that is a specific gate setting to 
detect the emissions of [35S]. 
Pulse and Chase Labeling of MHV-Infected Cells with [35S] Methionine 
Monoiayers of 17Cl-1 cells (confluent in 60-mm dish, 1.5xle>6 cells per dish) were 
infected with MHV-JHM at an MOI of 10. One hour later, virus inoculum was replaced 
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with DMEM supplemented with actinomycin D at a final concentration of 2 µg/ml. At 
5.5 hr after infection, the media was replaced with methionine-free media for 30 min. 
The infected-cells were then labeled with 200 µCi of [3sS] methionine (Translabel, ICN, 
Costa Mesa, CA) per ml, per f>O-mm dish for 30 min. At the end of labeling, the media 
was removed, cells were washed twice with cold PBS. Cells were then lysed by the 
addition of 300 µl/dish (1.5 X 1<>6 cells) of 2X lysis buffer, containing 4% SDS, 3% 
DTI, 40% glycerol and 0.0625 M Tris-HCl, pH 6.8. Cell lysates were harvested and 
stored at -70°C. For the chase experiment, after labeling for 30 min, the labeling media 
was removed, and 2 ml of DMEM containing a tenfold excess of unlabeled methionine 
(3 mM) and cysteine (4 mM) (Gibco BRL, Gaithersberg, MD) were added. Incubation 
periods are as indicated in the Results section. Following the chase, cell lysates were 
prepared and stored at -7CfC until analyzed. 
[ 32P] Orthophosphate Labeling of Phosphoproteins 
DBT cells in f>O-mm dishes were infected with MHV-JHM for 1 hr at 31>C. Then, 
the virus inoculum was replaced with DMEM media supplemented with 5 % FCS. At 
6.5 hr after infection, cells were first starved in DMEM free of phosphate (Gibco-BRL, 
Gaithersberg, MD) for 30 min and then labeled with 1 mCi of [32P] orthophosphate 
carrier free (Amersham Corp., Arlington Height, IL) in lml DMEM free of phosphate 
per f>O-mm dish for 2 hr. At the end of labeling, cells were washed twice with cold PBS 
and harvested as described above, to be used in the immunoprecipitation. 
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Vaccinia Recombinant Virus Expression System 
Recombinant vaccinia virus (vTF7-3), which expresses T7 DNA-dependent RNA 
polymerase, was generously provided by Dr. Bernard Moss (National Institutes of 
Health, Bethesda, MD). The virus was propagated on monolayer cultures of rabbit 
kidney cells (RK-13) provided by Dr. Richard Moyer (Florida State University, 
Gairnesville, FL). RK-13 cells were maintained in DMEM containing 10% FCS. 
vTF7-3 stocks were prepared on monolayers of RK-13 cells. Briefly, monolayers 
of RK-13 cells in a 150-mm dish (approximately 1 X 107 of cells) were infected with 
vTF7-3 at an MOI of 0.1. The virus inoculum was removed from the dish after a 1-hr 
incubation at 37°C, and 35 ml of DMEM containing 2% FCS was added. The dishes 
were incubated at 37°C for 3 days subsequently. 
Progeny virus was harvested 72 hour after infection. The virus-infected cells were 
first scraped from the bottom of the culture dish with a rubber policeman in the presence 
of the culture media. The whole mixture was transferred to a 50-ml falcon tube and 
centrifuged at 1,300 x g for 10 min in a table top silencer centrifuge. The supernatant 
was transferred to sterile tubes, labeled Fraction I and frozen at -1CfC. The cell pellet 
was resuspended in 2 ml of unsupplemented DMEM. This suspension was then frozen 
in an ethanol-dry ice bath for 10 min and thawed in a 37°C water bath for 15 min. The 
freeze-thaw process was repeated twice. After the third thawing, the tube was 
centrifuged at 1,300 x g for 10 min in a table top silencer centrifuge. The supernatant 
was transferred to tubes labeled Fraction II and frozen at -70°C. Two milliliters of 
unsupplemented DMEM were added to the cell-debris pellet and mixed. This-tube was 
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labeled as Fraction Ill and was frozen at -7ffC. The results from plaque assay (which 
is done in the same way as for MHV except using RK-13 cells as indicator cells) of 
Fractions I, Il and ID demonstrated that virus titers of Fraction I was 1 ;25 X 1()8 pfu/ml, 
Fraction Il: 2.5 X 109 pfu/ml, Fraction ID: 3.0 X 109 pfu/ml. 
A cDNA clone, pT7-NBgl, representing the 5'-most 5.3-kb sequence ofMHV-JHM, 
was used in an in vivo expression system (Fuerst et al., 1986) with some modifications. 
Briefly, DBT cells in a 60-mm dish, 90% confluent, were infected with vTF7-3 at an 
MOI of 5 for 45 min and were then transfected with pT7-NBgl by using lipofectin-
mediated transfection (Felgner et al., 1987; Makino, et al., 1991). Five micrograms of 
pT7-NBgl DNA and 10 µl of lipofectin (1 mg/ml, Gibco BRL, Gaithersberg, MD) were 
mixed with 500 µl of unsupplemented MEM and kept at room temperature for 10 min. 
The mixture was used to transfect the recombinant vaccinia virus vTF7-3-infected DBT 
cells at 37°c for 1 hr. One hour after transfection, the transfection mixture was 
removed and replaced with MEM supplemented with 5% FCS and incubated at 3'PC. 
Four hours after-infection, cells were starved for methionine for 30 min and labeled with 
[ 35S] methionine at a concentration of 200 µCi/ml/dish for two hrs. Cell lysates were 
then prepared as described above, using 300 µl 2X lysis buffer/dish, and were used for 
immunoprecipitation. 
Immunoprecipitation and SDS-PAGE 
Lysates from MHV-JHM infected or mock-infected cells were immunoprecipitated 
using anti-647, anti-p28, or preimmune serum as previously described (Balcer et al., 
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1989). Briefly, 100 µl of lysates were mixed with 5 µl antiserum and 1 ml 
immunoprecipitation buffer [RIPA: 0.5% Triton X-100, 0.1 % SDS, 300 mM NaCl, 4 
mM EDTA and 50 mM Tris-Cl (pH 7.4)], and incubated at 4°C overnight. Thirty 
microliters of protein A-Sepharose beads (Pharmacia, Piscataway, NJ) in 1: 1 RIPA were 
added to each tube. The reaction was incubated for additional 4 hrs at 4 °C with gentle 
rocking. The beads were then pelleted by centrifuging at 10,000 x g for 2 min and were 
washed three times with 1 ml of RIP A and the fourth time with 1 ml of 50 mM Tris-
HCl, pH 7.5. The bead complexes were resuspended in 50 µl of 2X Laemmli sample 
buffer, boiled for 2 min and centrifuged at 10,000 x g for 6 min at room temperature. 
The supernatant was loaded onto 10% polyacrylamide gel containing 0.1 % SDS. After 
electrophoresis at 15 mA (constant current) for 4 hrs, the gel was fixed in 40% methanol 
and 7% acetic acid for 30 min and enhanced with Kodak intensify (Dupont, Boston, 
MA) for 60 min, vacuum dried at 80°C and exposed to Kodak X-ray film at -700C. 
RNA Transfection of Temperature Sensitive Mutant MHV-Infected Cells 
Plasmid DNAs were linearized by EcoR I digestion and transcribed with T7 RNA 
polymerase as previously described (Soe et al., 1987). RNA transfection was done as 
previously described (Makino et al., 1991). Briefly, DBT cells about 60%-70% 
confluent in 60-mm dishes (number of cells, approximately 1.5 x H>6) were infected with 
ts mutant virus at an MOI of 10 for 1 hr at 33°C. The RNA-Lipofectin mixture was 
prepared as follows: 
1) Dilute 10 µg RNA to be transfected in 100 µl unsupplemented MEM in 12.x 75 mm 
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polystyrene tube, mix gently. 
2) Dilute 10· µl lipofectin (1 mg/ml, stock, Gibco-BRL, Gaithersberg, MD) in 100 µl 
unsupplemented MEM, mix gently. 
3) Mix above tubes 1) and 2) together gently, let it sit at room temperature for 10 min, 
and then add another 300 µl unsupplemented MEM, mix gently. 
After one hour of virus absorption, virus inoculum was aspirated and the dishes 
were washed once with PBS. The RNA-lipofectin mixture was added to one dish and 
lipofectin only diluted with unsupplemented MEM was added to another dish. The 
dishes were swirled and incubated at 33°C for 3 hr with rocking every 15 min ( 4 hr, 
after-infection). The transfection mixture was replaced with supplemented MEM, and 
the dishes were then shifted to 39.S°C and incubated for additional 12-14 hr (16-18 hr, 
after-infection). The extent of CPE was recorded under a microscope. The supernatant 
from each dish was harvested by centrifuging the supernatant for 10 min at 1,300 x g 
and stored at -700C until use. 
Construction of Plasmid pT7-DE6 
A schematic diagram of the construction of pT7-DE6 is shown in Figs. 6 and 7. 
PCR site-directed mutagenesis (Hutchison et al., 1978) was used to replace six 
nucleotides CTCTCA, at position 31to36 of the 5'-most of pT7-DE5-w3. pT7-DE5-w3 
was developed by Makino in 1989 (Makino et al., 1989). Primer B52 and B20 are listed 
in Table 1. Primer B52 contains a marker sequence, TAAGGC, which will allow 
specific detection of recombinant RNAs by RT-PCR. The pT7-DE5-w3 DNA was 
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Figure 6. Schematic diagram of DI-containing constructs for RNA recombination. 
The plasmid pT7-DE6 contains the entire sequence of DissE (Makino et al., 1988) and 
a 6-nucleotide marker (recognized by primer B53), which is represented by black bar. 
The white bar represents the second 6-nucleotide marker recognized by primer B 83. 
The marker sequences were introduced by PCR mutagenesis as described in the 
Materials and Methods section. The dot-filled box represents the 601-nucleotide 
sequence from the 3 '-end of the nucleocapsid gene of MHV. The restriction sites used 
for constructing these plasmids are indicated. T7 in the box represents the T7 promoter 
on the DI-containing plasmids. 
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Figure 7. Schematic diagram of the construction of pT7-DE6. The plasmid pT7-
DE5-W3 contains the entire sequence of DlssE (Makino et al., 1988). A 6-nucleotide 
marker is represented by the black bar. The marker sequence was introduced by PCR 
site specific mutagenesis as described in the Materials and Methods section. The box 
represents the entire nucleotide sequence of DlssE. The restriction sites used ·for 
construction are indicated. Arrowhead represents the T7 promoter on the plasmid. Star 
indicates that the primer B52 contains the 6 nucleotide marker sequence. 
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TABLE 1. SEQUENCE OF OLIGONUCLEOTIDES USED IN THIS STUDY 
NAME SEQUENCE BINDING POSITION DIRECTION 
89 CGCTCTTAACTAGTTTGTCC GENE 1 3736-3755 REV 
810 GGACAAACTAGTTAAGAGCG GENE 1 3736-3755 FWD 
813 TATGAATTCTCAGAGACGTTGTCTGC GENE 1 3531-3547 FWD 
814 ATTAGATCTTGGTGTTATACATGAACC GENE 1 4212-4230 REV 
819 GACTTCTAGAGATGCTTCCGAACGCA GENE 1 271-286 FWD 
820 CTAGAAGCTTGCCGGATGTCACAGAC GENE 1 801-816 REV 
829 GATGAATTCTATAAGAGTGATTGGCG GENE 1 1-17 FWD 
830 CATGGATCCATTTGAAGCCGAGACCG GENE 1 230-251 REV 
833 ATGGCGTCCGTACGTACCTAA GENE 1 13-33 FWD 
834 GTGGTTCCTTGACTTTCTGT GENE 1 139-159 FWD 
844 TCGCCATAGTCCTCAAGACCCTTG GENE 1 1012-1035 REV 
852 CCGTACGTACCTAAGGCACTCTAAAACTCTTGTAG GENE 1 20-54 FWD 
853 CCGTACGTACCTAAGGC GENE 1 20-36 FWD 
862 TATTACTAGTAGATCTGCCGCAGAC GENE 1 5263-5277 REV 
881 GACTCTATCCTCTCCGAGCTTCAAACCG GENE 1 3411-3474 FWD 
882 TTGAAGCTCGGAGAGGATAGAGTCTTC GENE 1 3441-3470 REV 
883 GACTCTATCCTCTCC GENE 1 3444-3459 FWD 
8101 TTACCATGGCCGCTTCTCTGTATAGTTCTTTGGTCCCTC GENE 1 9263-9290 FWD 
8102 ACTGAATTCGCTATTAAGGAGTGACAAGACGCCC GENE 1 11800-11824 REV 
~ 
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digested with SnaB I/ Stu I, producing 3.8-kb and 0.437-kb DNA fragments. The 3.8-
kb fragment was isolated through 0.7% low melting gel (Seaplaque, FMC Bioproducts, 
Rockland, ME) purification (Maniatis et al., 1989). Again, pT7-DE5-w3 DNA was 
used as template to engineer a 6 nucleotide marker sequence by PCR site-directed 
mutagenesis using B52, which contains the marker sequence, and B20. The resulting 
PCR product was digested by SnaB II Stu I to get the 437 bp fragment. Ligation of the 
3.8-kb and the 437 bp fragments resulted a new plasmid designated pT7-DE6 (Fig. 7). 
The 6-nucleotide marker sequence on the plasmid pT7-DE6 was verified by double 
stranded DNA sequencing using Sanger's chain termination method (Sanger et al., 1977) 
with primer B30. 
Construction of Plasmid p1i-DN 
A schematic diagram of the construction of pT7-DN is shown in Figs. 8. Plasmid 
pT7-DE6 DNA was digested with Stu I/Spe I to generate 3.2-kb and 1-kb fragments, 
and separated on a 1 % low melting gel. The 3.2-kb fragment was isolated. pT7-NBgl 
DNA was digested with Stu I/Spe I to generate 3.4-kb and 3.26-kb fragments and was 
separated on 1 % low melting gel. The 3.26-kb fragment was isolated. Two fragments, 
3.2-kb from pT7-DE6 and 3.26-kb from pT7-NBgl, were ligated and the resulting 
plasmid was named pT7-DN (Figs. 6 and 8). The pT7-DN sequence was verified by 
DNA sequencing using Sanger's chain termination method (Sanger et al., 1977) and by 
PCR analysis. 
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Figure 8. Schematic diagram of the construction of pT7-DN. The plasmid pT7-DE6 
contains the entire sequence of DlssE and a 6-nucleotide marker that is represented by 
the black bar. The detailed construction procedure was described in the Materials and 
Methods section. The rectangle represents the viral sequence. The restriction sites used 
for construction are indicated. Arrowhead represents the T7 promoter on the plasmid. 
The hatch box represents the 3.2 kb fragment that was cut out from pT7-NBgl and insert 
into pT7-DE6. The resulting plasmid is designated pT7-DN. 
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Construction of Plasmid pT7-DN6m 
PCR site-directed mutagenesis was used to construct plasmid pT7-DN6m (Figs. 6 
and 9), by employing two internal primers and two outside primers as previously 
described by Hutchison et al., 1978. Primers 98 and B82 were used in the first PCR 
reaction to generate the first fragment by using cDNA amplified from RNAs extracted 
from MHV-JHM-infected cells. Primer pair B9 and B81 were used to g~nerate the 
second fragment. Both fragments were purified through Magic PCR mini prep 
(Promega, Madison, WI) and were used as templates in a third PCR reaction using two 
outside primers 98 and B9. The final PCR products were digested by Spe I/Sph I and 
purified by low melting gel. pT7-DN6 DNA was digested by Spe I/Sph I to generate 
6.6-kb and 0.4-kb fragments. The 6.6-kb fragment was dephosphorylated by CIP and 
gel purified. The 6.6-kb fragment of pT7-DN6 was ligated to the final PCR-generated 
fragment oontaining the second marker sequence. The resulting plasmid was designated 
pT7-DN6m. 
Reverse Tramcription and Polymerase Chain Reaction (PCR) Amplllication 
The first strand cDNA was synthesized with the Reverse Transcriptase (Seikagaku 
America, Inc.) from total RNAs extracted from MHV-JHM-infected cells by using 
random hexamer (Gibco-BRL, Gaithersberg, MD), according to the suggested protocol 
of the manufacturer. The reaction was prepared as follows: 1 µg RNA, 100 pmole of 
random hexamer mixture, 40 units of RNasin, 1.0 mM each dCTP, dATP, dGTP, 
dTTP, 5 µl of reverse transcription buffer and 20 units of Reverse Transcriptase in a 
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Figure 9. Schematic diagram of the construction of pT7-DN6m. The second 6-
nucleotide marker sequence, which is represented by the black bar at the 3 '-end of the 
clone, was introduced by PCR mutagenesis as previously described by Hutchison et al., 
1978. The detailed construction procedure was described in the Materials and Methods 
section. The restriction sites used for construction are indicated. Arrowhead represents 
the T7 promoter on the plasmid. Stars indicate that both primers B81 and B82 contain 
the 6 nucleotide marker sequence. 
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final volume of 30 µl. The reaction mixture was incubated at 42°C for 1 hr and heated 
to 75°C for 2 min to inactivate the reverse transcriptase, then the reaction tube was 
transferred onto ice. One third of the reaction mixture from the reverse transcription 
reaction was used in a standard PCR amplification reaction. The PCR reaction was 
assembled as follows: 10 µl of template from RT reaction containing 2 to 10 ng DNA, 
1 unit Taq polymerase (Boehringer Mannheim, Indianapolis, IN), 200 nM of each 
primer, 10 mM Tris-HCl, pH 8.3, 1 mM MgC12, 50 mM KCl, 1.0 mM each dCTP, 
dATP, dGTP, dTTP, in a final volume 100 µl. The sample was overlaid with 100 µl 
mineral oil (Sigma, St. Louis, MO), and a PCR thermal cycler (Model 480, Perkin 
Elmer Cetus, Norwalk, CT) was used to carry out the cycling. The program for each 
cycle consisted of 1 min at 94°C, 1 min at 55°C (the annealing temperature is dependent 
on the G/C content of the primers), and 2 min at 72°C, 30 cycles, was used. To 
improve the specificity of the PCR amplification, hot start was used by heating the 
reaction to 94°C for 5 min before the addition of Taq polymerase. The result of PCR 
amplification was monitored by running 10 µl of the reaction mixture on a 1 % agarose 
gel. 
CHAPTER IV 
RESULTS 
Generation of Fusion Antiserum Anti-647 
As a first step toward identifying the proteolytic processing products of the 
polymerase polyprotein of MHV-JHM, I developed an antiserum against a specific 
portion of the viral polymerase polyprotein. The region of interest was adjacent to p28, 
which is an amino-terminal product of polymerase polyprotein (Denison et al., 1987; 
Soe et al., 1987; Baker et al., 1989) (Fig. 5 see Materials and Methods). To produce 
large amounts of the domain of interest, I cloned a cDNA encoding this region into a 
bacteria fusion expression vector, pGEX-KG (Fig. 5). The construction of the 
expression plasmid is described in the Materials and Methods. Briefly, a 647-nucleotide 
Xho I fragment (nucleotide positions 1129 to 1776 of the 5 '-end of the polymerase gene 
of MHV-JHM) was excised from pT7-NBgl DNA and cloned into an Xho I site in the 
polylinker of the expression vector pGEX-KG. The resulting plasmid, named pGEX-
647, was used to transform E. @ti DH 5a. The expression of the fusion protein is 
under the control of the tac promoter (Smith et al., 1988). The tac promoter is 
expressed at a low level under normal growth conditions. Expression of fusion-genes 
under the control of the tac promoter is highly induced upon the addition of IPTG 
(Amann et al., 1985). Addition of IPTG induced the high expression of the fusion 
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protein in bacteria and resulted in the synthesis of a 53 kDa polypeptide (Fig. 10). The 
53 kDa fusion protein was detected in the insoluble pellet of bacteria lysates (Fig. 10, 
lanes 1,. 3 and 6), but not in the supernatant (Fig. 10, lanes 2, 4 and 7). This fusion 
protein was absent in the cell extracts obtained from IPTG-induced E . .@Ii DH 5a cells 
transformed with pGEX-KG plasmid without insert (Fig. 10, lanes 11 to 14). The 
observed molecular mass of the fusion protein, approximately 53 kDa, correlated with 
the predicted mass of a fusion protein consisting of the GST and the viral protein (53.3 
kDa). The 53 kDa viral fusion protein from five samples as shown in Fig. 10 was cut 
out, smashed in PBS, mixed with complete or incomplete freund's adjuvant and injected 
into a rabbit as indicated in Table 2. Blood samples were taken 10 days after the third 
and fourth injections, and the titer of the antiserum was monitored by ELISA (Table 2). 
Ten days after third injection, the ELISA titer of the rabbit serum reached a value of 
0.057 as measured at 0.D.490 when the preimmune serum has a value of 0.009. After 
fourth injection, the ELISA titer of the rabbit serum reached a value of 0.901. The 
ELISA results indicate that a significant antibody response was generated against the 
GST-647 viral fusion protein. The antibody thus generated is designated anti-647. 
Determining the Specuicity of Anti-647 by Immunoprecipitation Analysis 
To determine the specificity of the anti-647 antibody, I used the antiserum to 
immunoprecipitate in vitro translated products of pT7-N27 (Fig. 11). pT7-N27 encodes 
p28, PCP-1 and the region against which the antiserum was generated. Plasmid pT7-
N27 was transcribed and translated in an in vitro system (see Materials and Methods). 
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Figure 10. Expression of OST-fusion protein in ,E.gili. The soluble and pellet 
fractions were analyz:ed by SDS-PAGE to determine the expression of the GST-647 viral 
fusion protein. The gel was stained with 0.25% commassie brilliant blue as described 
in the Material and Methods. W: whole cell lysate, P: pellet, S: supernatant, I: induced 
by IPTG, U: uninduced. M: molecular weight marker proteins. The GST-647 viral 
fusion protein is indicated by an arrowhead. Samples in lanes 1 and 2 were induced 
with IPTG for 1 hr; lanes 3 and 4, 2 hrs; and lanes 5-14, 3 hrs. Molecular mass 
standards are indicated at the right of the gel in kilodaltons. 
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Table 2. Generation of anti-647 antiserum 
DAYS (PI) INJECTION1 ELISA TITER2 
0 OST-fusion protein + 
Complete freund's adjuvant 
30 OST-fusion protein + 
Incomplete freund's adjuvant 
60 OST-fusion protein + 
Incomplete freund's adjuvant 
70 
90 OST-fusion protein + 
Incomplete freund's adjuvant 
100 
1 0.5 ml/site, four sites (two subcutaneous and two intramuscular). 
2 O.D.490 of the lx10-2 dilution of the anti-647 antiserum. 
PI= post injection. 
0.009 
0.057 
0.901 
52 
53 
Figure 11. Schematic diagram of the MHV-JHM polymerase gene and plasmid pT7-
N27. The positions of p28, the 647-nucleotide region designated by ** used for 
generating the GST-fusion antiserum, the papa.in-like cysteine proteinase domain 1 (PCP-
1), the predicted papain-like cysteine proteinase domain 2 (PCP-2) and the putative polio 
virus 3C-like proteinase domains (3C) are shown. Plasmid pT7-N27 contains sequence 
encoding p28, PCP-1 and the region used to generate anti-647 antiserum. 
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The primary translation product is 128 k:Da, however, it has been shown by in vitro 
translation studies that PCP-1 cleaves p28 from the 128 k:Da precursor protein, 
generating two products, 100 k:Da and 28 k:Da (Baker et al., 1993; and Fig. 12, lane 1). 
The protein products were analyzed by immunoprecipitation and SDS-PAGE. Anti-647 
immunoprecipitated one protein band around 100 k:Da (Fig. 12, lane 3). Anti-p28 
antibody immunoprecipitated a small processed product, p28, and the uncleaved 
precursor polyprotein of 128 k:Da (Fig. 12, lane 2). The immunoprecipitation result 
demonstrates that the antibody anti-647 binds to the product of the polymerase 
polyprotein of the coronavirus. 
Detecting the Proc~d Products of the Polymerase Polyprotein of MHV In Vivo 
To establish the optimal pulse-labeling protocol for MHV-JHM-infected 17Cl-1 cell, 
l 7Cl-1 cells-infected with MHV-IHM were pulse labeled with [35S] methionine at a 
concentration of 200 µCi/ml/60-mm dish for 2 hrs from 7 hr after infection. The cell 
lysates were prepared at various time points after pulse labeling using 2X lysis buffer 
(see Materials and Methods). 10 µl of each lysate were subjected to TCA precipitation 
and liquid scintillation counting analysis. The result from this analysis (Fig. 13) showed 
that radioactivity continued to be incorporated into newly synthesized protein in virus-
infected 17Cl-1 cells in a linear fashion during the 2-hr labeling period. Based on the 
result, I concluded that the concentration of the [35S] methionine used in this experiment 
(200 µCi/ml/60-mm dish) was in the proper range for pulse-labeling. 
To identify the proteolytic processing products of the polymerase polyprotein of 
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Figure 12. lmmunoprecipitation of in vitro translated products from the MHV-JHM 
polymerase gene. Lineariud plasmid pTI-N27 was transcribed and translated in the 
presence of [35S] methionine in an in vitro transcription and translation system. The 
translation products were analyud by 10% SDS-PAGE directly (lane 1) or after 
immunoprecipitation with anti-p28 (lane 2) or anti-647 (lane 3). Lane M contained 14C-
labeled molecular marker polypeptides. Molecular mass standards are given in 
kilodaltons on the right. 
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Figure 13. [35S] methionine incorporation analysis in 17Cl-1 cells. MHV-JHM-infected 
17Cl-1 cells were pulse labeled with [35S] methionine for 2 hrs at 7 hr after-infection. 
Whole cell lysates were prepared at various time points using 2X lysis buffer (see 
Materials and Methods). The proteins in a 10 µl sample of virus-infected cell lysates 
(1130 of the total lysates prepared from 1.5 X 1<>6 cells) were first TCA precipitated and 
then the amout of incorporated [35S] methionine were assessed by scintillation counting. 
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MHV-JHM, I determined which viral protein product in virus-infected cells can be 
immunoprecipitated by the anti-647 antiserum. Metabolic-labeling and 
immunoprecipitation experiments were carried out. The MHV-JHM infected l 7Cl-1 
cells were pulse labeled with [35S] methionine for 90 min at 7 hr after-infection. When 
the labeled cell lysates were immunoprecipitated with anti-647, a predominant protein 
band of approximately 65 kDa that is specific to infected cells was detected (Fig. 14, 
lane 4). The relative molecular weight of this protein was calculated by protein mobility 
versus molecular weight standard, it is approximately 65 kDa. The protein thus detected 
by immunoprecipitation was designated p65. It was not observed in mock-infected cells 
(Fig. 14, lane 3). In addition, two other viral protein bands (Fig. 14, lane 4) (as 
indicated by p73 and the upper band by the arrow) were also coimmunoprecipitated by 
anti-647. One protein migrated to a position about 73 kDa in molecular weight, another 
protein was approximately 250 kDa. 
In parallel experiments, p28 was immunoprecipitated by anti-p28 antibody (Fig. 14, 
lane 6). The presence of p28, the amino-terminal product of the polymerase polyprotein 
indicates that the MHV polymerase gene was being translated during the pulse-labeling 
experiment. No specific bands were detected using preimmune serum (Fig. 14, lanes 
1 and 2). The specific immunoprecipitation of a 65 kDa protein, using anti-647 antibody 
directed against the region downstream of p28, indicates that p65 is the polymerase 
polyprotein product adjacent to p28. 
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Figure 14. Detection of viral proteins encoded by the polymerase gene in MHV-JHM 
infected l 7Cl-1 cells by immunoprecipitation using anti-647 antiserum. Immuno-
precipitates of whole cell lysates prepared from MHV-JHM-infected cells or mock-
infected cells labeled with [35S] methionine from 7.0 to 8.5 hr after-infection were 
analyzed on 10% SDS-PAGE. Lanes: Products immunoprecipitated from mock-infected 
cells (lanes 1, 3 and 5) or from MHV-JHM-infected cells (lanes 2, 4 and 6) with 
preimmune serum, anti-647 or anti-p28, as indicated. Arrowheads indicate viral proteins 
p28, p73 and p65. The arrow indicates a viral protein about 250 kDa. Molecular 
weight markers are labeled in kilodaltons on the left of the gel. 
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Determining the Intracellular Proteolytic Proc~ing of the Polymerase Polyprotein 
It has been shown that the polymerase polyprotein of coronavirus undergoes 
proteolytic processing to release protein products (Denison, et al., 1987; 1991; Baker, 
et al., 1989; 1993). The N-terminal product released from the polyprotein is p28. Our 
results indicate that p65 is a processed product from the polymerase polyprotein. 
However, additional bands of p73 kDa and - 250 kDa were also detected using anti-
64 7. Because p65 together with p73 and - 250 kDa protein can be detected by using 
the same anti-647, it is possible that these proteins share the same epitope recognized 
by anti-647. During the course of polyprotein processing, precursor protein usually 
appears first and then is processed into smaller protein products as demonstrated in 
poliovirus polyprotein studies (Rueckert et al., 1979). 
To examine the intracellular turnover rate and processing of the p73 and p65 
proteins, I performed pulse and chase experiments. Virus-infected cells were labeled 
for 30 min at 7 hr after infection and chased for various lengths of time with media 
containing 10 times the normal concentration of cold methionine. When the labeled 
lysates were immunoprecipitated with anti-647 (Fig. 15), only p73 was detected after the 
30 min pulse. p73 steadily decreased along the course of chase, and at the end of chase 
it disappeared. p65 was not detected at time zero of chase, but it began to appear after 
15 min of chase. p65 gradually accumulated up to 2 hrs of chase suggesting that p65 
is a relatively stable protein. The accumulation of p65 was concomitant with the 
disappearance of p73 during the chase. These immunoprecipitation results suggest to 
us that p73 is the precursor of p65. 
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Figure 15. Immunoprecipitation of the viral proteins encoded by the polymerase gene 
from MHV-JHM infected 17Cl-1 cell lysates by using anti-647. MHV-JHM infected 
cells were pulse labeled with (35S] methionine at 7 hr after-infection for 30 min and 
chased with excess cold methionine for various time periods, as indicated above the 
lanes. Cell lysates were immunoprecipitated with anti-647 and analyzed by 10% SDS-
PAGE as described in the Materials and Methods. "M" stands for immunoprecipitation 
products from pulse-labeled mock-infected cell lysates. Arrowheads indicate the specific 
immunoprecipitation products, p73 and p65; the arrow indicates an additional high 
molecular weight protein band immunoprecipitated by anti-647. Molecular weight 
markers are labeled in kilodaltons on the left of the gel. 
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The protein band about 250 kDa was evident at the beginning of the chase and decreased 
along the course of 120 min chase (Fig. 15). The 250 kDa protein is detected at very 
low level after the 30 min pulse labeling and a precursor and product relationship could 
not be determined from the result of immunoprecipitation of the MHV-infected cell 
lysates. Additional antibody needs to be developed to determine if there is a precursor 
and product relationship between the p73 or p65 and the 250 kDa protein. This large 
protein may be the primary translation product of ORF la and potentially subject to 
multiple proteolytic processing events. 
In parallel experiments, the same lysate generated in the pulse-chase experiment was 
immunoprecipitated with anti-p28 monospecific peptide antibody (Fig. 16). p28 was 
present throughout the entire chase period, indicating that p28 is a relatively stable 
protein. When preimmune serum of anti-647 was used in the immunoprecipitation of 
the pulse-chase labeled cell lysates, no viral proteins were detected (Fig. 17). Based 
on the results of the pulse-chase-labeling experiments, immunoprecipitation and SDS-
P AGE analyses I conclude that p73 is a precursor to p65 and that p65, like p28, is a 
stable protein product of the polymerase polyprotein in coronavirus-infected cells. 
Determining Whether p28, p73 and p65 Are Phosphoproteins 
p28, p73 and p65 are located at the N-terminal portion of the polymerase 
polyprotein. These proteins may play an important role in viral transcription and 
replication as subunits of the replicase of coronavirus. Phosphorylation has been shown 
to be important in the regulation of biological activities of many proteins involved in 
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Figure 16. Immunoprecipitation of pulse and chase labeled proteins encoded by the 
polymerase gene from MHV-JHM infected 17Cl-1 cells by using anti-p28. MHV-JHM 
infected cells were pulse labeled with [35S] methionine at 7 hr after-infection for 30 min 
and chased with excess cold methionine for various time periods as indicated above the 
lanes. Cell lysates were immunoprecipitated with anti-p28 and analyzed by 10% SDS-
PAGE. "M" stands for immunoprecipitation products from pulse-labeled mock-infected 
cell lysates. The arrowhead indicates the specific immunoprecipitation product p28. 
Molecular weight markers are labeled in kilodaltons on the left of the gel. 
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Figure 17. lmmunoprecipitation of pulse and chase labeled proteins encoded by the 
polymerase gene in the MHV-JHM infected 17Cl-1 cells using preimmune serum of anti-
647. MHV-JHM infected cells were pulse labeled with [35S] methionine at 7 hr after-
infection for 30 min and chased with excess cold methionine for various time periods, 
as indicated above the lanes. Cell lysates were immunoprecipitated with preimmune 
rabbit serum and analyzed by 10% SDS-PAGE. "M" stands for immunoprecipitation 
products from pulse-labeled mock-infected cell extracts. Molecular weight markers are 
labeled in kilodaltons on the left of the gel. 
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DNA and RNA synthesis. It has been demonstrated that many proteins involved in the 
viral transcription and replication are phosphoproteins (Gill et al., 1986). 
To determine whether p28, p73 and p65 are phosphoproteins, [32P] orthophosphate-
labeling and immunoprecipitation experiments were done. MHV-infected cells were 
labeled with [32P] orthophosphate for 2 hrs, and whole cell lysate were prepared for 
immunoprecipitation with antibodies, anti-p28, anti-647 and monoclonal anti-
nucleocapsid antibody. The proteins immunoprecipitated from the lysates were analyzed 
by 10% SOS-PAGE (Fig. 18). The nucleocapsid protein is a phosphoprotein of 50 kDa 
(Stohlman et al., 1979) and was detected from MHV-infected cell lysates (Fig. 18, lanes 
5 and 6). There were no differences between the mock-infected cells and virus-infected 
cells using anti-p28 (Fig. 18, lanes 1 and 2), or using anti-647 (Fig. 18, lanes 3 and 4), 
indicating that there was no detection of phosphorylated p28, p73 or p65. Thus, from 
the above observations I concluded that p73, p65 and p28 are not phosphorylated. 
Determining if PCP-1 or PCP-2 Cleaves p73 or p65 from the Polyprotein In Vitro 
In the first ORF of the polymerase gene, there are three potential proteinase domains 
PCP-1, PCP-2 and 3C. The catalytic activity of the 5'-most proteinase domain PCP-1 
has been confirmed by site-directed mutagenesis and in vitro translation and 
immunoprecipitation (Balcer et al., 1989; 1993). To determine if PCP-1 or PCP-2 
cleaves p73 from the polyprotein or cleaves p73 to p65 in vitro, I used two cDNA 
clones, pT7-NBgl and pT7-NA6 that contain these domains (Fig. 19). Proteins were 
translated in vitro from these plasmids and were immunoprecipitated by using anti-647 
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Figure 18. Immunoprecipitation of [32P] orthophosphate-labeled MHV proteins from the 
MHV-infected cell lysates. MHV-JHM infected cells or mock-infected cells were pulse 
labeled for 2 hrs from 7 to 9 hr after infection. [32P] orthophosphate-labeled cell extracts 
were immunoprecipitated with antiserum as indicated above the lanes. The 
immunoprecipitates were analyzed by 10% SDS-PAGE. Mock-infected extracts were in 
lanes 1, 3 and 5, and MHV-JHM-infected cell extracts were in lanes 2, 4 and 6. The 
specific immunoprecipitation product (N: nucleocapsid protein) is indicated by 
arrowhead on the right of the gel. Molecular weight markers are labeled in kilodaltons 
on the left of the gel. 
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Figure 19. Schematic representation of the MHV-JHM polymerase gene and the cDNA 
clones used for in vitro transcription and translation studies. The positions of p28, the 
647-nucleotide region used for generating the OST-fusion antiserum, the papain-like 
cysteine proteinase domain 1 (PCP-1), the predicted papain-like cysteine proteinase 
domain 2 (PCP-2) and the putative polio virus 3C-like proteinase domains (3C) are 
shown. Plasmids pT7-NBgl and pT7-NA6 contain 5.3-kb and 6.8-kb nucleotide 
sequences respectively, from the 5'-most end of the MHV-JHM polymerase gene. 
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and anti-p28 antibodies. Viral proteins translated in the presence of [35S] methionine in 
vitro from pTI-NBgl representing the 5'-most 5.3-kb (including PCP-1) and pTI-NA6 
representing the 5' most 6.8-kb (including PCP-1 and PCP-2) sequence of polymerase 
gene were used in the immunoprecipitation and SOS-PAGE analyses. The sequence 
analysis of these cDNA clones predicts that pTI-NBgl encodes a 188 kDa protein 
including the PCP-1 domain, whereas pTI-NA6 encodes a 215 kDa protein including 
both PCP-1 and PCP-2 domains (Fig. 19). Anti-647 was able to immunoprecipitate two 
protein bands, 215 kDa being the precursor and 186 kDa being the large processed 
product from translations of pTI-NA6 (Fig. 20, lane 4); and to immunoprecipitate two 
protein bands, 188 kDa being the precursor and 160 kDa being the large processed 
product from translation of pTI-NBgl (Fig. 20, lane 5). However, neither p73 nor p65 
was detected (Fig. 20, lanes 4 and 5), indicating that neither PCP-1 nor PCP-2 is 
responsible for cleaving p73 or p65 from the polyprotein in vitro. As a positive control, 
anti-p28 antibody immunoprecipitated the 215 kDa precursor protein and a small 
processed product p28 from the translation of pTI-NA6; 188 kDa precursor protein and 
a small processed product p28 from translation of pTI-NBgl (Fig. 20, lanes 6 and 7). 
These results indicate that translation of pTI-NA6 does generate the precursor protein 
of 215 kDa and that PCP-1 is active, as indicated by the release of p28 and p186 (Fig. 
20, lanes 4 and 6) from the precursor protein. Such proteolytic processing can also 
being seen from the immunoprecipitation of the translation product of pTI-NBgl (Fig. 
20, lanes 5 and 7). The results from in vitro transcription and translation and 
immunoprecipitation analyses of pTI-NA6 and pTI-NBgl indicate that neither PCP-I nor 
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Figure 20. Immunoprecipitation analysis of translation products of pT7-NBgl and pT7-
NA6 using anti-p28 and anti-647. Linearized plasmids pT7-NBgl and pT7-NA6 were 
transcribed and translated in the presence of [35S] methionine and rabbit reticulocyte 
lysates in an in vitro transcription and translation system. The translation products were 
analyzed by SDS-PAGE directly (Lanes 1 and 2) or after immunoprecipitation with anti-
647 (lanes 4 and 5) or anti-p28 (lanes 6 and 7). Lane 3 contained 14C-labeled molecular 
marker polypeptides. Molecular mass standards are given in kilodaltons on the left. 
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PCP-2 is responsible for cleaving p73 or p65 from the polymerase polyprotein in vitro. 
Exp~ing the 5'-end of the Polymerase Gene via Recombinant Vaccinia Virus 
Exp~ion System 
The results obtained from in vitro transcription and translation and 
immunoprecipitation experiments described above may be affected by two possible 
factors. First, a host factor may be involved in processing p73 or p65; second, protein 
folding in vitro may not keep the optimal substrate conformation for the proteinase. To 
further investigate the proteolytic processing of polymerase polyprotein of coronavirus, 
I used an in vivo transient expression system. First, I determined if PCP-1 can cleave 
p73 or p65 from the polyprotein in vivo. A cDNA clone, pT7-NBgl, which contains the 
5'-most 5.3-kb sequence of polymerase gene including the PCP-1 (3.5-kb to 4.4-kb) 
domain was used in an in vivo recombinant vaccinia virus expression system (Fuerst et 
al., 1986). The vaccinia virus expression system takes advantage of the expression of 
the T7 polymerase from the recombinant vaccinia virus. The T7 polymerase expressed 
from the recombinant vaccinia virus then directs the expression of the T7 promoter-
containing plasmid pT7-NBgl introduced by transfection (Fig. 21). When mRNAs are 
transcribed from the input plasmid pT7-NBgl, the cellular translational machinery will 
translate these viral transcripts. Since the viral protein contains the PCP-1 proteinase 
domain, this proteinase will process the precursor protein within the cell. The beauty 
of this vaccinia expression system is that it allows us to study the proteolytic processing 
within the cell. 
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Figure 21. lliustration of recombinant vaccinia virus expression system. T7 DNA-
dependent RNA polymerase is expressed from the recombinant vaccinia vTF7-3 virus. 
The T7 polymerase subsequently drives the transcription of the transfected plasmid DNA 
which contains the T7 promoter. The cellular translation machinery will translate the 
mRNA generated from the incoming plasmid DNA. PCP-1 stands for the papain-like 
cysteine proteinase domain 1 of the polymerase polyprotein, and p28 is the amino-
terminal cleavage product of MHV-JHM. 
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DBT cells at 90% confluency were infected with recombinant vaccinia virus vTF7-3 for 
45 min, followed by the lipofectin mediated DNA transfection (Felgner et al., 1987; 
Makino et al., 1991) of pT7-NBgl DNA. At 4 hrs after-infection, cells were labeled 
with [35S] methionine at 200 µCi/ml for 2 hrs. Cell lysates were then prepared and used 
for immunoprecipitation (Fig. 22). pT7-NBgl has the capacity to encode a 188 kDa 
protein. PCP-1 cleaves p28 from the 188 kDa precursor protein, generating two 
products, 160 kDa and 28 kDa. Since both the 188 kDa and 160 kDa proteins contain 
the p65 domain, they should be immunoprecipitated by anti-647. Anti-p28 antibody 
immunoprecipitated a 28 kDa protein (Fig. 22, lane 2) demonstrating that the transfected 
plasmid pT7-NBgl DNA was being recogniud by the T7 polymerase, that its transcripts 
were being translated and that proteolytic processing was taking place within the cells. 
Immunoprecipitation of cell lysates with anti-647 revealed a protein band around 160 
kDa (Fig. 22, lane 4) which is specific to the pT7-NBgl transfected cell lysates. P73 
or p65 was not detected. Results from in vivo labeling and immunoprecipitation indicate 
that PCP-1 does not mediate the processing of p73 or p65 (Fig. 22). In fact, only the 
160 kDa protein was detected from the immunoprecipitation of labeled lysates prepared 
from vaccinia-infected and pT7-NBgl transfected cells. These data indicate that 
processing of the 188 kDa precursor protein was efficient and complete, because no 188 
kDa protein was detected by either anti-p28 or anti-647, which is in marked contrast· 
with the results of immunoprecipitation of in vitro translated products of pT7-NBgl (Fig. 
20, lanes 5 and 7) in which the precursor protein is always detectable. The p73 or p65 
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Figure 22. lmmunoprecipitation of proteins expressed from pT7-NBgl via recombinant 
virus expression system. [35S] methionine labeled lysates of vaccinia vTF7-3 virus-
infected, pT7-NBgl transfected cells were immunoprecipitated with anti-p28 and anti-647 
antibodies. The immunoprecipitates were analyzed on a 10% SDS-PAGE. Lanes 1 and 
3 are vaccinia virus-infected and mock transfected. Lanes 2 and 4 are vaccinia-infected 
and pT7-NBgl transfected. Anti-p28 peptide antibody was used in lanes 1 and 2, anti-
647 in lanes 3 and 4. The specific immunoprecipitation products p28 and p160 are 
indicated by an arrowhead. Molecular weight markers are labeled in kilodaltons on the 
left of the gel. 
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should be detected by immunoprecipitation using anti-647 antibody, if PCP-1 cleaves 
p73 or p65. Since there was no p73 or p65 detected in the immunoprecipitation of the 
vaccinia recombinant virus-infected, pTI-NBgl-DNA transfected cell lysate, I conclude 
that the PCP-1 domain is not responsible for cleaving p73 or p65 in vivo from the 
precursor polyprotein. 
Screenin& the Temperature Sensitive Mutants for Alteration in Polyprotein 
Proc~ing 
A series of temperature sensitive (ts) mutants has been generated by Barie and his 
colleagues (Schaad et al., 1990). These ts mutants do not synthesis RNA at 
nonpermisive temperature. The ts mutants have been divided into 6 complementation 
groups (Fig. 3). Genetic recombination analysis has revealed that these groups are 
mapped within the polymerase gene and are encoded in a linear array at the 5' of the 
genome, in the sequence of A, B, C, D, E from the 5'-end to the 3'-end of the 
polymerase gene (Fig. 3). To determine the function of the processed products of the 
polymerase polyprotein, I focused on complementation groups A and B mutants because 
they have been mapped to the 5'-end region that spans approximately 10 kb nucleotide 
sequences of the polymerase gene (Barie et al., 1990). This region encodes functional 
PCP-1, proposed PCP-2 domains, p28 and other proteins, and these proteins may have 
an important role in viral RNA synthesis. 
I investigated whether ts mutants of coronavirus are defective in proteolytic 
processing of the polymerase polyprotein and whether this kind of alteration in 
86 
proteolytic processing correlates with the ts phenotype. Initially, I screened the ts 
mutants for one which is defective in proteolytic processing of p28, by 
immunoprecipitation of cell lysates with anti-p28. Mutant virus-infected cells were pulse 
labeled with [35S] methionine at either the permissive (33°C) or nonpermissive (39.5°C) 
temperature. Results from immunoprecipitation of pulse labeled ts mutant NC 11-
infected 17Cl-l cell lysates indicated that production of p28 in ts NCll is significantly 
decreased at the nonpermissive temperature (39.5°C) (Fig. 23, lane NCll). 
Identifying Putative ts Mutations in ts Mutant NCll of MHV 
It is important to define the location of the mutation in these ts mutants. By 
identifying where the mutation is located in the gene and by verifying if it is a ts 
mutation, the function of viral protein involved in RNA synthesis and in generating the 
ts phenotype can be determined. Because the ts mutants I studied are defective in RNA 
synthesis, any structural defect in the protein or alteration in polyprotein processing will 
cause dysfunction of the protein involved in RNA synthesis. To search for possible 
mutations in the polymerase gene of the ts NC 11, both PCP-1 and p28 regions of ts 
mutant NCll were cloned and sequenced. A missense mutation, A to G, which caused 
amino acid change from asparagine to serine was identified at nucleotide position 391 
in the p28 domain from the 5'-end of the polymerase gene in ts mutant NCll (Fig. 24). 
Studies were next done to determine whether several revertants of NC 11 maintain 
the same mutation. The p28 and PCP-1 domains were cloned from these revertants 
from RNAs extracted from the ts NCH-infected cells and sequenced. The same 
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Figure 23. lmmunoprecipitation analysis of polyprotein processing of ts mutants 
infected 17Cl-1 cells labeled both at 33°C and 39.5°C. MHV-A59 and ts mutants 
infected l 7Cl-1 cells labeled with [35S] methionine at the permissive (33°C) and 
nonpermissive temperature (39.5°C). Arrow indicates p28. Samples in the lanes are 
indicated on the top of the lanes. LA 16 is a ts mutant belonging to complementation 
groups A and B. Molecular weight markers are labeled in kilodaltons on the left of the 
gel. 
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Figure 24. Sequence analysis of p28 and PCP-1 domains of ts mutant NC 11. Regions 
that were sequenced are indicated by dashed lines. MHV-A59 is the wild-type parental 
virus of ts NC 11 and NCl 1 revertants were obtained from Dr. Ralph Barie. Amino acid 
sequence is expressed in a single letter code above the nucleotide sequence. N: 
asparagine, I: isoleucine, S: serine, and V: valine. Kb: kilobase. 
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domains from wild type MHV-A59 were also cloned and sequenced as control. The 
sequence data indicated that the mutation at nucleotide position 391 reverted back to the 
wild type sequence in these revertants (Fig. 24). The sequencing data from ts mutant 
NCll and NCll revertants suggested (1) that mutation at 391 is a possible ts mutation 
because it was reverted back to wild type sequence in these revertants and (2) that a 
mutation in the p28 region possibly renders the virus incapable of synthesizing its RNA 
at 39.5°C. Furthermore, it also implied that p28 is involved in virus transcription and 
replication. However, I had not yet shown whether or not the mutation is functionally 
responsible for the ts phenotype. The definitive evidence to determine if a mutation is 
responsible for the ts phenotype is to replace the mutation with wild-type sequence and 
determine if the replacement of the mutation has "cured" the ts phenotype. The 
approach I took was to substitute the mutation at the 5 '-end of the polymerase gene in 
NCll with wild type sequence by providing DI RNA as the substrate in RNA 
recombination. 
Rescuing ts Mutant NCll of MHV by RNA Recombination 
It has been shown that viral recombination can occur between replicating viral RNAs 
and nonreplicating RNA fragments that were transfected into virus-infected cells (van 
der Most et al., 1992; Liao et al., 1992). It has also been shown that targeted RNA 
recombination can be used to successfully rescue the ts mutant which is defective in 
nucleocapsid formation, by using both the defective interfering (DI) particles and the 
RNA fragments as substrates (Koetzner et al., 1992; van der Most et al., .1992). I 
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obtained a defective interfering RNA DlssE-based plasmid, which contains the full 
sequence of a small DI particle DlssE (Makino et al., 1988; 1989) and used it in my ts 
mutant study. To facilitate the detection of the recombinant RNA molecules after RNA 
recombination, I engineered this plasmid to contain a 6 nucleotide marker sequence near 
the 5'-end of the viral untranslated sequence. This plasmid was designated pT7-DE6 
(Fig. 25). The pT7-DE6 has 864 nucleotides from the 5' most of the polymerase gene 
of MHV-JHM. This 5'-most 864 nucleotide fragment covers the mutation region in ts 
NCll (Fig. 24). 
I used pT7-DE6 RNA as substrate in targeted RNA recombination in order to 
substitute the mutation in the NCll with the wild-type sequence carried on the pT7-DE6 
RNA. If the recombinant virus turns out to be no longer temperature sensitive, then that 
will be the direct evidence that the mutation at nucleotide position 391 in NC 11 is 
responsible for the ts phenotype. I transfected the DE6 RNAs into ts mutant NCll-
infected cells by using lipofectin-mediated RNA transfection protocol (Fig. 26) (Feigner 
et al., 1987; Makino at al., 1991). Progeny viruses were harvested from the culture 
dishes 16 hr after RNA transfection, and total RNAs were extracted from the cell 
monolayers. 
To determine whether recombination has cured the ts phenotype, a plaque assay was 
carried out at both 33°C and 39.5°C. Significant viral titers were obtained at 33°C; 
however, no plaques were detected at 39.5°C, indicating that either no RNA 
recombination had taken place or that the RNA recombination had failed to "cure" the 
ts phenotype. To determine whether RNA recombination has taken place, RT-PCR 
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Figure 25. Structure of pTI-DE6 containing defective interfering RNA. A comparison 
between the sequences of DE6 RNA and those of standard MHV-JHM genomic RNA. 
DE6 contains the entire sequence of DlssE (Makino et al., 1988) and a 6 nucleotide 
marker (recognized by oligonucleotide primer B33), which is located at nucleotide 
position 31 to 36 at the 5'-end of the polymerase gene. DlssE is composed of three 
noncontiguous regions: I and II, which represent the first 864 nucleotides of the 5 '-end 
and an internal 748 nucleotides of the polymerase gene, and region III, which contains 
601 nucleotides from the 3'-end of parental MHV genome. 
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Figure 26. Strategy for RNA transfection and detection of recombinant RNAs. 
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amplification were performed to detect the recombinant RNA. I designed the upstream 
primer (Pl) (Fig. 27) specific for the marker sequence in DE6 RNA and the downstream 
primer (P2) specific for the ts mutant sequence around 5'-most 1-kb region (which does 
not exist in DE6 RNA) for amplifying the recombinant molecules in the PCR. The 
template RNAs extracted from the ts NCl 1 infected and pTI-DE6 RNA transfected cells 
were reverse transcribed and subsequently were amplyfied by PCR. The PCR products 
were analyzed by agarose gel electrophoresis. A specific band was detected in the RNA 
sample which was extracted from the ts NCH-infected and DE6 RNA-transfected cells 
(Fig. 28, lane 2) but not in the mock-transfected sample nor in negative control samples 
(Fig. 28, lanes 1, 3 and 4). 
The presence of the specific band indicates that the RNA recombination has occurred 
in our ts mutant infection and RNA transfection system. To determine if the mutation 
at the p28 region in NC 11 has been replaced by the wild-type sequence and where the 
crossover site is in recombinant RNA, I cloned the band from the PCR products 
generated from ts mutant NC 11-infected and DE6-transfected cells and sequenced several 
clones. 
It is relative easy to map out the locations of the crossover site because the ts NCl 1 
was generated from MHV-A59 strain and DE6 was derived from MHV-JHM strain. 
These two MHV strains have amino acid sequence identity above 95 % • Four clones 
were sequenced by the dideoxy chain-termination method of DNA sequencing (Sanger, 
et al., 1977). Two clones had 710 nucleotide sequence derived from DE6 and the other 
two clones had crossover sites at nucleotide positions 145 and 110 of the 5'-end of the 
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Figure 27. Specific primers designed to detect recombinant molecules. Primer B33 (P 1) 
was specific for marker sequence in the DE6, and primer B44 (P2) was specific for NC 
11 mutant sequence at the 5'-most 1-kb region of the polymerase gene, which is not 
present in DE6 RNA. Recombinant molecules are specifically amplified in RT-PCR 
analysis. 
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Figure 28. Detection of recombinant RNA by RT-PCR amplification. Total RNAs 
were isolated from NCll ts mutant virus-infected and DE6 RNA-transfected or mock-
transfected DBT cells, as described in Materials and Methods. The RNAs were reverse 
transcribed and the resulting cDNAs were amplified by PCR using B33 and B44. PCR 
products were analy:zed by 1.5% agarose gel electrophoresis and stained with ethidium 
bromide. Lane M: Haem molecular standard. Lane 1: RNA extracted from NCll .ts 
mutant-infected and mock-transfected cells. Lane 2: RNA extracted from NCll 
mutant-infected and DE6 RNA-transfected cells. Lanes 3 and 4: DE6 RNA with RNA 
from ts NCll-infected cells and DE6 DNA used as negative controls, respectively. The 
specific band in lane 2 is indicated by arrow. Molecular standards are labeled at the left 
of the gel. 
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Figure 29. Sequence analysis of recombinant molecules. Sequence comparison between 
ts mutant NC 11 (underline) derived from MHV-A59 and DE6 RNA (dark shade) 
derived from MHV-JHM. Identical sequences are represented by dots( ... ) which are 
not proportional to the number of the nucleotides. Sequence differences are expressed 
by letters. The sequence gap between dark shade sequence and light shade sequence 
represent the crossover site which could not be pinpointed with certainty because of the 
sequence identity between MHV-A59 and MHV-JHM in these areas. 
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These sequencing data indicated that the 5' sequences of the polymerase gene of ts 
mutant NC 11 were replaced by RNA recombination. To date, no recombinant virus 
which can grow at 39.5°C has been detected, although the mutation at position 391 in 
NCl 1 has been replaced by the wild-type sequence from DE6 RNA (Fig. 29), suggesting 
that NC 11 may have multiple mutations, which together with the mutation at nucleotide 
position 391 are responsible for the ts phenotype. 
Above data revealed that the 5'-end sequence of the polymerase gene of ts mutant 
can be replaced by targeted RNA recombination. This RNA recombination strategy will 
be useful to map and rescue the ts mutants of coronavirus. It demonstrated the 
feasibility of using RNA recombination to study the functions of the polymerase 
polyprotein products of coronavirus in ts mutants. 
CHAPTER V 
DISCUSSION 
The experiments described herein were designed to study the structure and function 
of the polymerase polyprotein of MHV. I have focused on identifying the proteolytic 
products of the polymerase polyprotein and the mechanisms by which these products are 
generated. The proteolytic processing of viral polyproteins has been shown to be 
important for viral RNA synthesis and replication in all RNA viruses (Krausslish et al., 
1988; Wellink et al., 1988; Dougherty et al., 1993). The results described in this report 
have identified the processed products p73 and p65 of the coronavirus polymerase 
polyprotein. In addition, I hypothesi7.e that these products are generated by the activity 
of the 3C like proteinase domain. These experiments have begun to unravel the 
proteolytic processing pathways of the polymerase polyprotein of MHV. 
Many RNA viruses express their genetic information by the synthesis of polyproteins 
that are posttranslationally cleaved to generate the functional viral gene products. 
Processing of virus precursor polyprotein in the cytosol has been shown to be mediated 
by the proteinases encoded by the virus itself (Strauss, 1990). Specifically, the 
poliovirus polyprotein contains two proteinases, 2A and 3C, which are responsible for 
processing the nonstructural polyprotein both in cis and trans (Palmenberg, 1990). 
Sindbis virus proteinase nonstructural protein 2 (nsP2) functions to cleave the 
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polyprotein both in cis and trans (Hardy et al., 1989). The nsP2 protein has been shown 
to play an important role in the temporal regulation of Sindbis virus RNA synthesis (de 
Groot et al., 1990). Coronavirus polymerase polyprotein has three proposed proteinases, 
PCP-1, PCP-2 and 3C. It has been shown that PCP-1 cleaves p28 from polyprotein in 
vitro (Baker et al., 1989). To identify the proteolytic processed products adjacent to 
p28, I developed a specific antiserum, anti-647, directed against that region downstream 
of p28. I have identified the processed products p73 and p65 of the coronavirus 
polymerase polyprotein from MHV-infected cells by immunoprecipitation using anti-64 7. 
The results of pulse-chase-labeling and immunoprecipitation experiments have revealed 
that p73 is the precursor of p65. Both p73 and p65 are located adjacent to p28 of the 
polymerase polyprotein (Fig. 30). These results are consistent with the recent 
observation that p65 is located downstream of p28 (Hughes et al., 1994) 
The results from this study have also demonstrated that several events are required 
in the proteolytic processing pathway to generate the processed protein products, p28, 
p73 and p65, of the MHV polymerase polyprotein. The first event in this proteolytic 
processing pathway is the autoproteolytic cleavage of the amino-terminal protein, p28. 
This cleavage occurs in cis and is mediated by the PCP-1 domain (Balcer et al., 1989). 
The second event in proteolytic processing pathway is the release of a 73 kDa protein 
from the polymerase polyprotein (Figs. 14 and 15). The 73 kDa protein is then further 
proteolytically processed to generate a 65 kDa mature protein product, possibly by a 
trans-acting proteinase as proposed (Fig. 30). The precursor and product relationship 
of p73 and p65 can be clearly established from the pulse and chase labeling and 
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Figure 30. Schematic representation of proteolytic processing scheme of the polymerase 
polyprotein of MHV-IHM. The small box on the 5'-end of gene 1 represents the region 
from which the peptide antibody anti-p28 was developed (Baker et al., 1989) The large 
black box represents the region from which a fusion antibody anti-647 was developed. 
The N-terminal product of the polymerase polyprotein is p28. p65 is adjacent to p28. 
The positions of the papain-like cysteine proteinase domain 1 (PCP-1), the predicted 
PCP-2 and the polio virus 3C-like proteinase domains (3C) are shown. The p28, p65 
and p73 proteins were detected in our immunoprecipitations by using anti-647 and anti-
p28 antibodies. P* is a putative protein cleavage product of p73. The question mark 
(?) represents the hypothesis that 3C-like proteinase domain is responsible for the 
cleavage of p73 from the polymerase polyprotein. 
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immunoprecipitation analysis (Fig. 15). Pulse and chase labeling and 
immunoprecipitation with the specific antisera had been used to determine the precursor 
and products relationship of poliovirus polyprotein from the poliovirus-infected cells 
(Summer et al., 1968). 
The proteolytic processing of the p73 and p65 seems mediated by two distinct 
proteinase activities. It was apparent that p28 and p73 were readily detectable only 30 
min after pulse-labeling and that the timing of the appearance of p28 and p73 is similar 
(see Figs. 15 and 16). Based on the above indirect evidence, I propose that like p28, 
p73 is generated by a cis-cleavage event. The appearence of p65 is delayed when 
compared with the appearence of p28 and p73. p65 begins to appear after 30 min of 
pulse-labeling and 15 min of chase, at least 15 min after the appearence of p28 and p73. 
The anti-647 was developed direct against a portion of a predicted polypeptide 
downstreams of p28. The results from immunoprecipitations using anti-647 indicate that 
p73 and p65 locate adjacent to C-terminal of p28, which is consistant with the report that 
two ts mutants were defective in the production of p65 at nonpermissive temperature and 
that p65 is a polypeptide of MHV-A59 ORFla, located next to p28 by using a fusion 
antibody against a portion of the polyprotein encoded by the 5'-end 2 kb sequences of 
the polymerase gene (Hughes et al., 1994). The cleavage of p73 to generate p65 is most 
likely in trans, since p65 is processed from the precursor protein p73 as shown in (Fig. 
30). It is unlikely that p73 contains any proteinase activity because there is no sequence 
homology in p73 domain to any known viral proteinases. Based on these results, I 
propose that this p73-to-p65 transition event is mediated by proteinase activity in trans. 
110 
One of the proteolytic processing pathways that leads to the generation of p65 is 
through p73 processing, as demonstrated by the pulse and chase experiment and 
immunoprecipitation analysis (Fig. 15). It is possible that other pathways may also 
exist. There may be a precursor that can be directly processed to generate p65. In 
addition, the precursor for p73 is not known yet. The 250 k:Da protein could be a 
candidate precursor for p73 or for p65. The 250 k:Da protein was present at the time 
uro of chase and gradually disappeared in the 2 hr course of chase (Fig. 15). p73 is 
also present at time uro of chase and disappeared in the chase (Fig. 15). It is likely 
that the 250 kDa protein is the precursor of p73, because I repeatly detect p73, p65 and 
250 kDa protein by using the same antibody. These results suggest that the 250 kDa 
protein shares an epitope with p73 and p65, and has similar kinetics of p73 during the 
chase. The results from the pulse and chase experiment and immunoprecipitation did 
not clearly show the precursor and product relationship between 250 kda protein and 
p73. What I believe is that p73 is only a intermediate precursor for p65 and that p73 
is processed from another precursor. It remains to be determined if the 250 kDa could 
be another precursor, in addition to p73, which could be directly processed into p65. 
The above ideas can be tested directly by immunoprecipitation of MHV-infected cells 
using a peptide antibody to be developed against a region within the p65 domain. If 
p73, p65 and 250 kDa protein can be immunoprecipitated by using a peptide antibody, 
it tells us that they have the identical epitope, indicating that they have the same protein 
portion but differ in siu. 
One issue as yet unsolved is which proteinase is responsible for cleaving p73 and 
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p65. The results of in vitro experiments have shown that the functional PCP-1 domain 
and the proposed PCP-2 domain were not responsible for the processing of p73 and p65 
(Fig. 20 lanes 4 and 5). It should be noted that a PCP-2 domain was proposed by 
Gorbalenya in 1989. Up to date, no one has shown that the proposed PCP-2 is active. 
It is possible that the polypeptides do not fold into the appropriate conformation for 
proteinase cleavage in an in vitro reaction. Both the processed products, p28 and pl60, 
and precursor 188 kDa translated from the pTI-NBgl RNA are readily detected by 
immunoprecipitation with anti-p28 and anti-64 7 antibodies. The PCP-1 domain on the 
precursor protein was functional, as indicated by release of p28 from the precursor 
protein (Fig. 20, lanes 6 and 7). It is consistent with previous observation that PCP-1 
acts in cis to release p28 from the precursor protein (Baker et el., 1989; 1993). If the 
assumption that protein folding affects the activity of PCP-1 to release p73 and p65 in 
an in vitro translation system is true, then p73 and p65 should be detectable from the in 
vivo expression of pTI-NBgl in DBT cells. 
The vaccinia recombinant virus transient-expression system has been used for 
numerous studies that examine the processing of RNA virus polyproteins. In general, 
the results from these studies mimic the authentic processing reactions observed in virus-
infected cells. One example is that the recent report using the vaccinia expression 
system to study the processing of nonstructural polyprotein and of Sindbis virus (Lemm 
et al., 1993). When I used pTI-NBgl DNA in the vaccinia expression system to study 
the processing of the coronavirus polymerase polyprotein, I found that the processed 
products p28 and pl60 were detected in the immunoprecipitation by using anti-p28 and 
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anti-647 antibodies respectively from radiolabeled vaccinia-infected and pT7-NBgl-
transfected DBT cell lysates (Fig. 22, lanes 2 and 4). This is the first in vivo evidence 
that PCP-1 is responsible for cleaving p28 from the polyprotein. No precursor p188 was 
detected from the DBT cell lysates, indicating that proteolytic processing in vivo, (DBT 
cells) is more efficient and complete as compared with that of the in vitro experiment 
(Figs. 12 and 20). Anti-647 antibody was able to immunoprecipitate the large product 
p160, which contains p73 and p65 domains, but it did not detect p73 or p65 from the 
same cell lysate, indicating that there was no cleavage of p73 or p65 from the precursor 
protein in the DBT cells-infected with vaccinia recombinant virus and transfected with 
pT7-NBgl DNA. The polyprotein processing in vivo (DBT cells), markedly differs from 
the polyprotein processing in vitro system, in the rabbit reticular lysate, from which I 
could detect both the precursor p188 and the products p160 and p28 (Fig. 20, lanes 5 
and 7). It is not known if some specific host factors that ameliorate the efficiency of the 
proteolytic processing may exist in DBT cells but not in the rabbit reticular lysate. 
PCP-1 is in functional both in vitro and in vivo systems (Baker et al., 1993; Figs. 20 
and 22), but PCP-1 is not responsible for cleaving p73 and p65 from the precursor 
protein. 
It is plausible to hypothesize that a proteinase other than PCP-1 is responsible for 
cleaving p73 and p65 from the polymerase polyprotein. The most favorable candidate 
for the proteinase that cleaves p73 and p65 is the 3C proteinase located at nearly the 
middle of the polymerase polyprotein. The results reported herein both from in vitro 
and in vivo studies are consistent with this hypothesis. 
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The functions of p73 and p65 are not yet clear. Presumably, these proteins act in 
certain steps of viral RNA transcription and replication. Sequence analysis (Soe et al., 
1987) has shown there is a potential zinc-binding domain located within the p65 region 
between nucleotide positions 1326 and 1408, which may encode a nucleic acid binding 
protein which is involved in viral RNA transcription and replication. Considering that 
p65 is a relative stable protein (Fig. 15), it is interesting to see that a stable protein with 
the nucleic acid binding property may function as one component of the polymerase 
complex in the RNA transcription and replication. 
A recent report by Denison showed that coronavirus RNA synthesis was blocked in 
virus-infected cells in the presence of cysteine proteinase inhibitor, E64d (Denison et al., 
1994). Further experiments revealed that the processing of the polymerase protein was 
blocked by E64d and that there was no p65 detectable in the MHV-infected cells, 
suggesting that continuous polyprotein processing is required for the RNA synthesis 
(Denison et al., 1994). These data suggest that continuous p65 production is required 
for coronavirus RNA synthesis. Similar findings have been documented for Sindbis 
virus (Shirako et al., 1994). Shirako and his colleague discovered that negative-strand 
RNA synthesis is blocked if the nonstructural polyprotein (P1234) processing to P123 
is blocked. The cleavage products, Pl, P2 and P3, processed from the precursor P123 
are required for positive-strand RNA synthesis (Shirako et al., 1994). These data 
indicate the essential role of polyprotein processing in virus replication. 
Further experiments are needed to determine whether the blockage by E64d is at the 
stage of p73 processing to p65 or at the level of generating p73. Such an experiment 
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may provide important information regarding the function of p73 and p65. If we can 
detect p73 but not p65 from the virus replication and E64d inhibition experiment, then 
the results would suggest that p73 to p65 processing is required for virus transcription 
and replication. Another possibility would be that nascent p65 is needed for RNA 
synthesis. In either case, the actual roles that p73 and p65 play in coronavirus RNA 
synthesis will become clearer. 
The proteolytic processing of the polymerase polyprotein plays an important role in 
poliovirus and Sindbis virus replication (Palmenberg, 1990; Shirako et al., 1994). In 
coronavirus, the role of the proteolytic processing in RNA synthesis has been explored 
both from ts mutants and wild type viruses (Baker et al.,1994; Denison et al., 1994). 
One of mutants, NC 11, is not only defective in RNA synthesis but also defective in p28 
production at nonpermissive temperature (Fig. 23). The cause of the diminished p28 
production is not known yet. There are at least two possibilities that could result in the 
defective production of p28. One possibility is that there is a defect in protein 
translation machinery at nonpermissive temperature, assuming that there is no problem 
in polyprotein processing. If that is the case, then all the viral protein synthesis will be 
diminished. The other possibility remains that there is a defect in polyprotein processing 
at nonpermissive temperature, assuming that the protein translation is fine. If that is the 
case, then the assumed precursor protein for p28 will be accumulated, because no 
precursor protein for p28 has been identified so far. These possibilities can be tested 
in the immunoprecipitation of ts mutants-infected cells by using anti-647 and anti-p28 
antibodies together with the antibodies to be developed against the other domains of the 
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polymerase polyprotein. 
It has been shown that polymerase polyprotein undergoes proteolytic processing to 
release smaller functional subunits (Denison et al., 1987; 1992; Baker et al., 1989; 
1993; Gao et al., 1994). If each cleavage product of the polymerase polyprotein belong 
to a separate complementation group, there will be at least 3 complementation groups 
then within the first 3 kb sequence of the 5 '-end of the polymerase gene. Since there 
is only one ts mutant group mapped to 5 kb sequence of the 5'-end of the polymerase 
gene, it is possible that several processed products of the polymerase polyprotein are 
needed to synthesize a certain species of RNAs. The ts mutants that have defects in 
these protein products will be complemeted as a single complemetation group because 
these protein products function in cis in virus replication. The other possibility is that 
these mature proteins conceivably participate in the various aspects of MHV RNA 
synthesis. If that is the case, then the ts mutant group A may fall into the p65 domain 
around nucleotide positions 957 to about 2670 of the 5 '-end of the polymerase gene. 
The actual cleavage site for p65 is not known yet. Previous mapping study of the ts 
mutants of MHV suggested that the defects of the group A mutants seemed not located 
in the p28 region (Barie, et al., 1990). It needs to be determined whether some of the 
group A mutants have ts mutations in the p65 domain and whether they can be rescued 
by RNA recombination using DI containing plasmids that carry wild-type sequences. 
These experiments will provide the genetic evidence for the function of p65 in RNA 
synthesis. 
The future studies I would like to propose are as follows: first, to determine the 
116 
function of p73 or p65 by an E64d inhibition experiment to see if E64d blocks p73 
processing and generation; second, to clone the functional 3C proteinase from MHV-
JHM and to characterize the 3C cDNA clone in an in vitro transcription and translation 
system. If the 3C clone is proteolytically functional, then it can be used to determine 
whether 3C cleaves p73 or p65 in trans both in an in vitro transcription and translation 
system and in an in vivo recombinant vaccinia virus expression system. This approach 
will test the hypothesis that JC-like proteinase is responsible for cleaving p73 or p65 
from the polymerase polyprotein. Third, the potential zinc-finger domain within the p65 
region can be tested to determine if the zinc-finger domain of p65 can bind radiolabeled 
RNA in an in vitro RNA mobility analysis. Fourth, the group A ts mutants which was 
mapped at the 5 '-end of the polymerase gene can be used to determine the function of 
p65 by identifying the mutation within the p65 domain. DI-mediated RNA 
recombination can then be applied to rescue the ts mutant, that has the defined mutation 
within the p65 domain. 
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